

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 22, 2003, 15:27:27 ; Search time 79 Seconds

(without alignments)
1688.403 Million cell updates/sec

Title: US-10-046-433-40

Perfect score: 1001
Sequence: 1 MAEPGSHSLARVGRTER.....LGRSNHLPRGLMDLTQCR 1001

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 908470 seqs, 133250620 residues

Word size : 0

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 150 summaries

Database : A Geneseq 101002:*

```

1: /SID32/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SID32/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SID32/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SID32/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SID32/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SID32/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SID32/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SID32/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SID32/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SID32/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SID32/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SID32/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SID32/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SID32/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SID32/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SID32/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SID32/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SID32/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SID32/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SID32/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SID32/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SID32/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SID32/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1001	100.0	1001	22	AA835333
2	877	87.6	1013	21	AA826179
3	708	70.7	1013	22	AA826190
4	704	70.3	750	22	AA835328
5	675	67.4	1013	22	AA838345
6	662	66.1	911	22	AA838350
7	621	62.0	870	22	AA838351
8	460	46.0	495	20	AA159972
9	249	24.9	363	22	AA838353
10	216	21.6	372	22	AA85768

11	150	15.0	147	208	21	AA853442	Human colon cancer
12	147	14.7	209	22	AA83849	Peptide fragment o	
13	117	11.7	209	22	AA83852	Amino acid sequenc	
14	96	9.6	105	21	AA826180	Human CASB619 prot	
15	56	5.6	52	22	AA83847	Peptide fragment o	
16	52	5.2	52	22	AA83848	Peptide fragment o	
17	45	4.5	52	22	AA83846	Peptide fragment o	
18	38	3.8	150	20	AA12274	Human 5' EST seque	
19	21	2.1	1027	22	AA870256	TR16-long receptor	
20	15	1.5	411	22	AA848372	Human SRS5 protein	
21	15	1.5	464	22	AA848377	Human SEC10 protei	
22	15	1.5	963	22	AA870255	TR16-short recepto	
23	14	1.4	50	22	AA839681	Peptide #7187 enco	
24	14	1.4	50	22	AA824346	Protein #6345 enco	
25	14	1.4	50	22	AA860397	Human brain expres	
26	14	1.4	50	22	AA873033	Human bone marrow	
27	14	1.4	50	22	AA819811	Peptide #6245 enco	
28	14	1.4	50	22	AA83257	Peptide #7294 enco	
29	14	1.4	50	23	ABG42877	Human peptide enco	
30	14	1.4	71	22	AAU21345	Human novel foetal	
31	14	1.4	78	22	AA870285	Peptide #29, Unid	
32	10	1.0	10	21	AA827114	Human CASB619 prot	
33	10	1.0	10	21	AA827115	Human CASB619 prot	
34	10	1.0	10	21	AA827116	Human CASB619 prot	
35	10	1.0	10	21	AA827117	Human CASB619 prot	
36	10	1.0	10	21	AA827118	Human CASB619 prot	
37	10	1.0	10	21	AA827119	Human CASB619 prot	
38	10	1.0	10	21	AA827120	Human CASB619 prot	
39	10	1.0	10	21	AA827121	Human CASB619 prot	
40	10	1.0	10	21	AA827122	Human CASB619 prot	
41	10	1.0	10	21	AA827123	Human CASB619 prot	
42	10	1.0	10	21	AA827124	Human CASB619 prot	
43	10	1.0	10	21	AA827125	Human CASB619 prot	
44	10	1.0	10	21	AA827126	Human CASB619 prot	
45	10	1.0	10	21	AA827127	Human CASB619 prot	
46	10	1.0	10	21	AA827128	Human CASB619 prot	
47	10	1.0	10	21	AA827129	Human CASB619 prot	
48	10	1.0	10	21	AA827130	Human CASB619 prot	
49	10	1.0	10	21	AA827131	Human CASB619 prot	
50	10	1.0	10	21	AA827132	Human CASB619 prot	
51	10	1.0	10	21	AA827133	Human CASB619 prot	
52	10	1.0	10	21	AA827134	Human CASB619 prot	
53	10	1.0	10	21	AA827135	Human CASB619 prot	
54	10	1.0	10	21	AA827136	Human CASB619 prot	
55	10	1.0	10	21	AA827137	Human CASB619 prot	
56	10	1.0	10	21	AA827138	Human CASB619 prot	
57	10	1.0	10	21	AA827139	Human CASB619 prot	
58	10	1.0	10	21	AA827140	Human CASB619 prot	
59	9	0.9	10	21	AA827141	Human CASB619 prot	
60	9	0.9	9	21	AA826181	Human CASB619 prot	
61	9	0.9	9	21	AA826182	Human CASB619 prot	
62	9	0.9	9	21	AA826183	Human CASB619 prot	
63	9	0.9	9	21	AA826184	Human CASB619 prot	
64	9	0.9	9	21	AA826185	Human CASB619 prot	
65	9	0.9	9	21	AA826186	Human CASB619 prot	
66	9	0.9	9	21	AA826187	Human CASB619 prot	
67	9	0.9	9	21	AA826188	Human CASB619 prot	
68	9	0.9	9	21	AA826189	Human CASB619 prot	
69	9	0.9	9	21	AA826190	Human CASB619 prot	
70	9	0.9	9	21	AA826191	Human CASB619 prot	
71	9	0.9	9	21	AA826192	Human CASB619 prot	
72	9	0.9	9	21	AA826193	Human CASB619 prot	
73	9	0.9	9	21	AA826194	Human CASB619 prot	
74	9	0.9	9	21	AA826195	Human CASB619 prot	
75	9	0.9	9	21	AA826196	Human CASB619 prot	
76	9	0.9	9	21	AA826197	Human CASB619 prot	
77	9	0.9	9	21	AA826198	Human CASB619 prot	
78	9	0.9	9	21	AA826199	Human CASB619 prot	
79	9	0.9	9	21	AA826200	Human CASB619 prot	
80	9	0.9	9	21	AA826201	Human CASB619 prot	
81	9	0.9	9	21	AA827101	Human CASB619 prot	
82	9	0.9	9	21	AA827102	Human CASB619 prot	
83	9	0.9	9	21	AA827103	Human CASB619 prot	
				21	AA827104	Human CASB619 prot	
				21	AA827105	Human CASB619 prot	

84	9	0.9	9	21	AAB37106	Human CASB619 prot
85	9	0.9	9	21	AAB27107	Human CASB619 prot
86	9	0.9	9	21	AAB27108	Human CASB619 prot
87	9	0.9	9	21	AAB27109	Human CASB619 prot
88	9	0.9	9	21	AAB27110	Human CASB619 prot
89	9	0.9	9	21	AAB27111	Human CASB619 prot
90	9	0.9	9	21	AAB27112	Human CASB619 prot
91	9	0.9	9	21	AAB27113	Human CASB619 prot
92	9	0.9	9	21	AAB27114	Human CASB619 prot
93	9	0.9	9	21	AAB27115	Human CASB619 prot
94	9	0.9	9	21	AAB27116	Human CASB619 prot
95	9	0.9	9	21	AAB27117	Human CASB619 prot
96	9	0.9	9	21	AAB27118	Human CASB619 prot
97	9	0.9	9	21	AAB27119	Human CASB619 prot
98	9	0.9	9	21	AAB27120	Human CASB619 prot
99	9	0.9	9	21	AAB27121	Human CASB619 prot
100	9	0.9	9	21	AAB27122	Human CASB619 prot
101	9	0.9	9	21	AAB27123	Human CASB619 prot
102	9	0.9	9	21	AAB27124	Human CASB619 prot
103	9	0.9	9	21	AAB27125	Human CASB619 prot
104	9	0.9	9	21	AAB27126	Human CASB619 prot
105	9	0.9	9	21	AAB27127	Human CASB619 prot
106	9	0.9	9	21	AAB27128	Human CASB619 prot
107	9	0.9	9	21	AAB27129	Human CASB619 prot
108	9	0.9	9	21	AAB27130	Human CASB619 prot
109	9	0.9	9	21	AAB27131	Human CASB619 prot
110	9	0.9	9	21	AAB27132	Human CASB619 prot
111	9	0.9	9	21	AAB27133	Human CASB619 prot
112	9	0.9	9	21	AAB27134	Human CASB619 prot
113	9	0.9	9	21	AAB27135	Human CASB619 prot
114	9	0.9	9	21	AAB27136	Human CASB619 prot
115	9	0.9	9	21	AAB27137	Human CASB619 prot
116	9	0.9	9	21	AAB27138	Human CASB619 prot
117	9	0.9	9	21	AAB27139	Human CASB619 prot
118	9	0.9	9	21	AAB27140	Human CASB619 prot
119	9	0.9	9	21	AAB27141	Human CASB619 prot
120	9	0.9	9	21	AAB27142	Human CASB619 prot
121	9	0.9	9	21	AAB27143	Human CASB619 prot
122	9	0.9	9	21	AAB27144	Human CASB619 prot
123	9	0.9	9	21	AAB27145	Human CASB619 prot
124	9	0.9	9	21	AAB27146	Human CASB619 prot
125	9	0.9	9	21	AAB27147	Human CASB619 prot
126	9	0.9	9	21	AAB27148	Human CASB619 prot
127	9	0.9	9	21	AAB27149	Human CASB619 prot
128	9	0.9	9	21	AAB27150	Human CASB619 prot
129	9	0.9	9	21	AAB27151	Human CASB619 prot
130	9	0.9	9	21	AAB27152	Human CASB619 prot
131	9	0.9	9	21	AAB27153	Human CASB619 prot
132	9	0.9	9	21	AAB27154	Human CASB619 prot
133	9	0.9	9	21	AAB27155	Human CASB619 prot
134	9	0.9	9	21	AAB27156	Human CASB619 prot
135	9	0.9	9	21	AAB27157	Human CASB619 prot
136	9	0.9	9	21	AAB27158	Human CASB619 prot
137	9	0.9	9	21	AAB27159	Human CASB619 prot
138	9	0.9	9	21	AAB27160	Human CASB619 prot
139	9	0.9	9	21	AAB27161	Human CASB619 prot
140	9	0.9	9	21	AAB27162	Human CASB619 prot
141	9	0.9	9	21	AAB27163	Human CASB619 prot
142	9	0.9	9	21	AAB27164	Human CASB619 prot
143	9	0.9	9	21	AAB27165	Human CASB619 prot
144	9	0.9	9	21	AAB27166	Human CASB619 prot
145	9	0.9	9	21	AAB27167	Human CASB619 prot
146	9	0.9	9	21	AAB27168	Human CASB619 prot
147	9	0.9	9	21	AAB27169	Human CASB619 prot
148	9	0.9	9	21	AAB27170	Human CASB619 prot
149	9	0.9	9	21	AAB27171	Human CASB619 prot
150	9	0.9	9	21	AAB27172	Human CASB619 prot

ALIGNMENTS

RESULT 1

QY	1	MAEGRSHHLSARVGRTERIRIPRLMRLMAGTAPVOTGTPELHACKSEHYEYTA	60
DB	1	MAEGRSHHLSARVGRTERIRIPRLMRLMAGTAPVOTGTPELHACKSEHYEYTA	60
QY	61	CDSTGSRVAVVPHTPGLCTSLDPVYKTECSFSCNAGEFLDMKDQSCPKCAGRSYLG	120
DB	61	CDSTGSRVAVVPHTPGLCTSLDPVYKTECSFSCNAGEFLDMKDQSCPKCAGRSYLG	120
QY	121	GIRFDEWDELPHGPASISANMEIDDSAEBSGTCTSKVPRDDYIAFNTDECTATMYA	180
DB	121	GIRFDEWDELPHGPASISANMEIDDSAEBSGTCTSKVPRDDYIAFNTDECTATMYA	180
QY	181	VNFKSGTAVFEYYPSSIIIEFPVONDCQPNADSRMKTTERGMEHSHVLEIRGN	240
DB	181	VNFKSGTAVFEYYPSSIIIEFPVONDCQPNADSRMKTTERGMEHSHVLEIRGN	240
QY	241	VLYWRTTAFSVWTKVPPVLRNIAITGVAITSECPCKGTADKQSSFCFLCPANSY	300
DB	241	VLYWRTTAFSVWTKVPPVLRNIAITGVAITSECPCKGTADKQSSFCFLCPANSY	300
QY	301	SNKGTSCHOCDDPKYSEKSSSCNVRPACTDXYTTHACDANGETOLMYMAKPKIC	360

```

Db 301 SNKGTSCHQCDPDKYSEKSSSCNVRPACTDKDYFHTHACDANGETOIMYMAKPKIC 360
Qy 361 SEDLEGAVKLPASGVKTHCPNCPGPFKTNNSQCPGYSYSGSDCTRCAPGTEPAVG 420
Db 361 SEDLEGAVKLPASGVKTHCPNCPGPFKTNNSQCPGYSYSGSDCTRCAPGTEPAVG 420
Qy 421 FEYKMNNTLPNTMETTVLSGINFYKGMTGWEVAGDHITTAAGASNDPMILTLVVGFR 480
Db 421 FEYKMNNTLPNTMETTVLSGINFYKGMTGWEVAGDHITTAAGASNDPMILTLVVGFR 480
Qy 481 PPOSVADTENKEVARITFEVETLCSVNCCLYPMVGVNSRTNTPVETWKSCKGOSYTYI 540
Db 481 PPOSVADTENKEVARITFEVETLCSVNCCLYPMVGVNSRTNTPVETWKSCKGOSYTYI 540
Qy 541 IEENTTSFTWAFORTTFHASKRYTNDVAKIYSINTVNWGVASYCRPCALEASDVGS 600
Db 541 IEENTTSFTWAFORTTFHASKRYTNDVAKIYSINTVNWGVASYCRPCALEASDVGS 600
Qy 601 SCTSCPAGYIIDRDSGTCHSCPNTILKAHOPYGVQACVPCGPGTKNNKIHSICVNDCTF 660
Db 601 SCTSCPAGYIIDRDSGTCHSCPNTILKAHOPYGVQACVPCGPGTKNNKIHSICVNDCTF 660
Qy 661 SRNTPTRTFNYSALANTVTLAAGSPFISKGLKYFHHFTLSLGNQGRMSVCTDNVTD 720
Db 661 SRNTPTRTFNYSALANTVTLAAGSPFISKGLKYFHHFTLSLGNQGRMSVCTDNVTD 720
Qy 721 LRIPBEGSSGSKITAVVCAVVIIPPEVTVGYKAGVSQPVSLADRLIGVTTMTLDGITS 780
Db 721 LRIPBEGSSGSKITAVVCAVVIIPPEVTVGYKAGVSQPVSLADRLIGVTTMTLDGITS 780
Qy 781 PALFPHLESIGIPDVYFFYSNDVTQSCSSGRSTTRVRSPOKTVPGSLLMGTSQDGT 840
Db 781 PALFPHLESIGIPDVYFFYSNDVTQSCSSGRSTTRVRSPOKTVPGSLLMGTSQDGT 840
Qy 841 CDGCFHFILMESAAACPLGADVHYAIVSSCVAGIOKTTYVWREPKLCSGGISLPEQRVT 900
Db 841 CDGCFHFILMESAAACPLGADVHYAIVSSCVAGIOKTTYVWREPKLCSGGISLPEQRVT 900
Qy 901 ICTTIDFPMKLVGASGCTAIIITLVLTCTYWKXNQKLEYISKLVMNATLKDCLPAADS 960
Db 901 ICTTIDFPMKLVGASGCTAIIITLVLTCTYWKXNQKLEYISKLVMNATLKDCLPAADS 960
Qy 961 CAIMEGDEVDDLIFTSKNHSLSGRSNHLPGRGLMDLTQCR 1001
Db 961 CAIMEGDEVDDLIFTSKNHSLSGRSNHLPGRGLMDLTQCR 1001

RESULT 2
AAB26179
ID AAB26179 standard; Protein; 1013 AA.
XX
AC AAB26179;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein #1.
XX
KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
XX
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.

```

```

XX
PI Bruck CEM, Casasat J, Coche T, Vinals De Basols YC;
XX
DR WPI; 2000-664923/64.
XX
DR N-PSDB; AAA95442.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX
XX
PS Claim 4, Page 54-56; 68pp; English.
CC The present sequence comprises the human CASB619 protein sequence. This
CC protein is thought to be specifically or over-expressed in tumour cells,
CC and so can be used as a target for antigen-specific immune responses
CC which can cause destruction of the tumour cell. In addition, the protein
CC and gene can be used in cancer diagnosis, in the treatment of autoimmune
CC diseases and in vaccines against cancer and autoimmune disease. The
CC invention provides a number of epitopes derived from the protein which
CC can be used as immunogens.
XX
SQ Sequence 1013 AA;
XX
Query Match 87.6%; Score 877; DB 21; Length 1013;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 977; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 MAEPGSHLSARVRGRTERRIPRLWRLIMAGTAPQVOTGTPELHACKESHYEYTA 60
Db 1 MAEPGSHLSARVRGRTERRIPRLWRLIMAGTAPQVOTGTPELHACKESHYEYTA 60
Qy 61 COSTGRMVAVWHTGCLTSLPDPVKTEGSCSNAGSFLDMKDSCKPCAERSLGT 120
Db 61 COSTGRMVAVWHTGCLTSLPDPVKTEGSCSNAGSFLDMKDSCKPCAERSLGT 120
Qy 121 GIRFDEMDLPHGFASLSANMELDASAESTGCTSSKWPVRGDIYAFNTDECTATIMYA 180
Db 121 GIRFDEMDLPHGFASLSANMELDASAESTGCTSSKWPVRGDIYAFNTDECTATIMYA 180
Qy 181 VNLKSGTVNFEYYPDSSIIIEFFVQNDQCPNADSRMKTKTEKGWEHSEYELNGNN 240
Db 181 VNLKSGTVNFEYYPDSSIIIEFFVQNDQCPNADSRMKTKTEKGWEHSEYELNGNN 240
Qy 241 VLYWRTTASVWTKVQKPLVNRVIAITGVAYTSEGPCRGYADQSSFCULCPANSY 300
Db 241 VLYWRTTASVWTKVQKPLVNRVIAITGVAYTSEGPCRGYADQSSFCULCPANSY 300
Qy 301 SNKGTSCHQCDPDKYSEKSSSCNVRPACTDKDYFHTHACDANGETOIMYMAKPKIC 360
Db 301 SNKGTSCHQCDPDKYSEKSSSCNVRPACTDKDYFHTHACDANGETOIMYMAKPKIC 360
Qy 361 SEDLEGAVKLPASGVKTHCPNCPGPFKTNNSQCPGYSYSGSDCTRCAPGTEPAVG 420
Db 361 SEDLEGAVKLPASGVKTHCPNCPGPFKTNNSQCPGYSYSGSDCTRCAPGTEPAVG 420
Qy 421 FEYKMNNTLPNTMETTVLSGINFYKGMTGWEVAGDHITTAAGASNDPMILTLVVGFR 480
Db 421 FEYKMNNTLPNTMETTVLSGINFYKGMTGWEVAGDHITTAAGASNDPMILTLVVGFR 480
Qy 481 PPOSVADTENKEVARITFEVETLCSVNCCLYPMVGVNSRTNTPVETWKSCKGOSYTYI 540
Db 481 PPOSVADTENKEVARITFEVETLCSVNCCLYPMVGVNSRTNTPVETWKSCKGOSYTYI 540
Qy 541 IEENTTSFTWAFORTTFHASKRYTNDVAKIYSINTVNWGVASYCRPCALEASDVGS 600
Db 541 IEENTTSFTWAFORTTFHASKRYTNDVAKIYSINTVNWGVASYCRPCALEASDVGS 600
Qy 601 SCTSCPAGYIIDRDSGTCHSCPNTILKAHOPYGVQACVPCGPGTKNNKIHSICVNDCTF 660
Db 601 SCTSCPAGYIIDRDSGTCHSCPNTILKAHOPYGVQACVPCGPGTKNNKIHSICVNDCTF 660
Qy 661 SRNTPTRTFNYSALANTVTLAAGSPFISKGLKYFHHFTLSLGNQGRMSVCTDNVTD 720

```

Db 661 SRNPTPTFNYSALANTVTLAAGPSTSGKLTFFHFTLSLGNQGRKMSVCTDNVTD 720
 Qy 721 LRIPEGSGFSKSIYAVYCOAVIIPPEVTGYKAGVSSQPSVLADRLIGVTDMTLDGITS 780
 Db 721 LRIPEGSGFSKSIYAVYCOAVIIPPEVTGYKAGVSSQPSVLADRLIGVTDMTLDGITS 780
 Qy 781 PAELFHLBSLGIPIPVYFFRYRNDVTQSCSGSRSTIRVRCSPQKTVPGSLIPGTCSDGT 840
 Db 781 PAELFHLBSLGIPIPVYFFRYRNDVTQSCSGSRSTIRVRCSPQKTVPGSLIPGTCSDGT 840
 Qy 841 CDGCFHFLMSAAACPCSVADYHAYVSSVAGIOKTTYVWRBPKLGGGSLPEQSVT 900
 Db 841 CDGCFHFLMSAAACPCSVADYHAYVSSVAGIOKTTYVWRBPKLGGGSLPEQSVT 900
 Qy 901 ICKTIDFWLKVGISAGCTTALLTVLTCYFWKQKQLEKYKSLVMNATLKDCLPAADS 960
 Db 901 ICKTIDFWLKVGISAGCTTALLTVLTCYFWKQKQLEKYKSLVMNATLKDCLPAADS 960
 Qy 961 CAIMEGEVEDDLIFTSK 978
 Db 961 CAIMEGEVEDDLIFTSK 978
 RESULT 3
 AAU12190
 ID AAU12190 standard; Protein, 1013 AA.
 XX
 AC AAU12190;
 DT 24-OCT-2001 (first entry)
 DE Human PRO4985 polypeptide sequence.
 XX
 KM Human secretory and transmembrane; PRO; mammalian; cancer; lung;
 KM breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
 KM cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
 KM adipocyte; A-peptide; factor VIIa; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO200140466-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 01-DEC-2000; 2000WO-US32678.
 XX
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 02-DEC-1999; 99WO-US28551.
 PR 02-DEC-1999; 99WO-US28564.
 PR 02-DEC-1999; 99WO-US28565.
 PR 09-DEC-1999; 99US-0170262.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30939.
 PR 30-DEC-1999; 99WO-US31243.
 PR 06-JAN-2000; 2000WO-US00277.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 01-MAR-2000; 2000WO-US05601.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 10-NOV-2000; 2000WO-US30873.

XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, DeForge L, Deanyers L, Filvaroff E, Gao W,
 XX Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2001-408281/43.
 DR N-PSDB; AAS21262.
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing
 PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
 PT lung, breast, prostate, cervical
 PS Claim 12; Fig 38; 813pp; English.
 XX
 CC AAU12172-AAU12446 represent novel human secretory and transmembrane
 CC PRO polypeptides. The PRO polypeptides are useful to detect other
 CC PRO polypeptides, to link bioactive molecules to cells expressing
 CC PRO polypeptides, to modulate biological activities of cells expressing
 CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample.
 CC Some of the 275 sequences are also useful to stimulate the release of
 CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
 CC proliferation or differentiation of chondrocytes, the proliferation or
 CC gene expression in pericyte cells, the release of proteoglycans from
 CC cartilage, the proliferation of inner ear utricular supporting cells or
 CC of T-lymphocytes, the release of a cytokine from peripheral blood
 CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
 CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
 CC skeletal muscle cells or by adipocytes, or inhibit binding of A-peptide
 CC to factor VIIa. The PRO polypeptides can be used in assays to identify
 CC molecules involved in binding interactions. The polynucleotides encoding
 CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy.
 CC
 XX
 SQ Sequence 1013 AA;
 Query Match 70.7%; Score 708; DB 22; Length 1013;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 708; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 169 NTDECTATLMAVAVLKKSGTVNFEYYPDSIIIEFFVQNDQCPNADDSRMKTEKGW 228
 Db 169 NTDECTATLMAVAVLKKSGTVNFEYYPDSIIIEFFVQNDQCPNADDSRMKTEKGW 228
 Qy 229 EFHSEVLRGNVLYMRTTAPASVWTKPKPYLVNNAITGVAYTSECPCKPGTYADKOG 288
 Db 229 EFHSEVLRGNVLYMRTTAPASVWTKPKPYLVNNAITGVAYTSECPCKPGTYADKOG 288
 Qy 289 SSFCKLCPANSYSNKGTSCHQCDPDKYSKSSGSSCNVRACTDKDIFYHTACDANGET 348
 Db 289 SSFCKLCPANSYSNKGTSCHQCDPDKYSKSSGSSCNVRACTDKDIFYHTACDANGET 348
 Qy 349 QLMYKMAKPKYCSSEDLGAVVLPASGVKTHCPNCPGFFKTNSTCPCPYGSYNSGDC 408
 Db 349 QLMYKMAKPKYCSSEDLGAVVLPASGVKTHCPNCPGFFKTNSTCPCPYGSYNSGDC 408
 Qy 409 TRCPAGTEPAVGFYKWMNTLPTMETTVLSGINFERYKMGVGEVADHDHYTAAGADND 468
 Db 409 TRCPAGTEPAVGFYKWMNTLPTMETTVLSGINFERYKMGVGEVADHDHYTAAGADND 468
 Qy 469 FMILTLVVGFRPQSVADTENKEVARITVFETTLCSNCELYFMGVNSRTTPEWT 528
 Db 469 FMILTLVVGFRPQSVADTENKEVARITVFETTLCSNCELYFMGVNSRTTPEWT 528
 Qy 529 KGSKGOSYTYIIIEENTTSFTNAFQRTTTHASRKYTNDAKIYSINVTVMNGVASYC 588
 Db 529 KGSKGOSYTYIIIEENTTSFTNAFQRTTTHASRKYTNDAKIYSINVTVMNGVASYC 588
 Qy 589 RPKALEASDVSGSCTSCPAGYIYIDBSGTHSCPPNTILAKHQPVGVAQVCPCPGTKNN 648

Dh	589	RPCALIASDVSSCTSCSPAGIYIDIRDSESTHCSCFPNTILKHHQYGVQACVPCGPBKGN	648
Qy	649	KIHSLCYVNDCTFSRNTPTRTFNVPFSLANVTLAGSPSFLSKLKTFFHFTLSLGNQG	708
Dh	649	KIHSLCYNDCTFSRNTPTRTFNVPFSLANVTLAGSPSFLSKLKTFFHFTLSLGNQG	708
Qy	709	RKMSVCTDNVDLRLRPEGSGSFGFSKITAYVCAVITLPEVTVGKAGVSSQPSVLADRLIG	768
Dh	709	RKMSVCTDNVDLRLRPEEBSGFSFKSITAYVCAVITLPEVTVGKAGVSSQPSVLADRLIG	768
Qy	769	VTTDDTLTLDGITSFPAFLFLHSLGIPDVVFYFRSNDVTVSCSGSGSTTIRRCSPQKTVPG	828
Dh	769	VTTDDTLTLDGITSFPAFLFLHSLGIPDVVFYFRSNDVTVSCSGSGSTTIRRCSPQKTVPG	828
Qy	829	SLLLPQTSDDCTCGGCGNFHFLMESAAACPLCSVDHYAIVSSCYAGIQ	876
Dh	829	SLLLPQTSDDCTCGGCGNFHFLMESAAACPLCSVDHYAIVSSCYAGIQ	876

Oy	298	NSYSKKESTCHQCDPKYKSSKSSCNVPACTDQDYFTTHAACANGSTOLMYKAP	357
Dd	47	NSYSKGETSCHQCDPKYKSSKSSCNVPACTDQDYFTTHAACANGSTOLMYKAP	106
Oy	358	KICSIEDLEGAVKLPASGVKTHCPBCNDBFFKTKNNSTQCPYGSYSNGSDCTRCPAGTEP	417
Dd	107	KICSIEDLEGAVKLPASGVKTHCPBCNDBFFKTKNNSTQCPYGSYSNGSDCTRCPAGTEP	166
Oy	418	AVGFEYKMMWNLPTNNMETTVLSGINFECYKMTGMEVAGDHIIYTPAAGSNDDEMLITLVP	477
Dd	167	AVGFEYKMMWNLPTNNMETTVLSGINFECYKMTGMEVAGDHIIYTPAAGSNDDEMLITLVP	226
Oy	478	GFRPPOSVMADTENKEVARIITFVETLCSVNCCLYFVMGVNSRSTNTPVEITWKSCKGOSY	537
Dd	227	GFRPPOSVMADTENKEVARIITFVETLCSVNCCLYFVMGVNSRSTNTPVEITWKSCKGOSY	286
Oy	538	TYIIIEENTTSFTMAFORTPHFHSKRKYTDVAKIYSINTNMNGVASYCRCALEASD	597
Dd	287	TYIIIEENTTSFTMAFORTPHFHSKRKYTDVAKIYSINTNMNGVASYCRCALEASD	346
Oy	598	VGSSECTSPAGYIYIDROSGETCHSCPPTILKHAQPYVOACVCEPETKNNKIKHSICYND	657
Dd	347	VGSSECTSPAGYIYIDROSGETCHSCPPTILKHAQPYVOACVCEPETKNNKIKHSICYND	406
Oy	658	CTFSRNTPTRTFNYPFSALANTVTLAAGPSFTSKGLKYFHHFTLSICGNQGRMSVCTDN	717
Dd	407	CTFSRNTPTRTFNYPFSALANTVTLAAGPSFTSKGLKYFHHFTLSICGNQGRMSVCTDN	466
Oy	718	VTDLRIPGEGSGFSKSIITAYVCOAVIIPREYTGKAGVSSOPVSLADRILGVTTDMTLDG	777
Dd	467	VTDLRIPGEGSGFSKSIITAYVCOAVIIPREYTGKAGVSSOPVSLADRILGVTTDMTLDG	526
Oy	778	ITSPALFHLHESLGI PDVIFPYRSNDVTQSSSGRSTTIVRCSPOKTVPGSILLPGTCS	837
Dd	527	ITSPALFHLHESLGI PDVIFPYRSNDVTQSSSGRSTTIVRCSPOKTVPGSILLPGTCS	586
Oy	838	DGTCDCGCFHFLHMSAACPICSVADYHAIYVSSCVAGIOKTTYVMREPKCSGGSISLPEQ	897
Dd	587	DGTCDCGCFHFLHMSAACPICSVADYHAIYVSSCVAGIOKTTYVMREPKCSGGSISLPEQ	646
Oy	898	RVTIICKTIDFWLKVGISAGCTTALLTVLTCYFWKKNQKLEYKYSKLVMMATLKDCLPA	957
Dd	647	RVTIICKTIDFWLKVGISAGCTTALLTVLTCYFWKKNQKLEYKYSKLVMMATLKDCLPA	706
Oy	958	ADSCAIMEGDEVEDDLFTSKNHSIGSNLPRGLMDLTQCR 1001	
Dd	707	ADSCAIMEGDEVEDDLFTSKNHSIGSNLPRGLMDLTQCR 750	

/note= "transmembrane domain"

FT XX WO200131003-A1.
 XX PD 03-MAY-2001.
 XX PF 30-OCT-2000; 2000WO-FR03032.
 XX PR 29-OCT-1999; 99FR-0013629.
 XX PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX DR WPI; 2001-328651/34.
 XX DR N-PSDB; AAF89765.
 XX PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 PT identifying agents for treating tumours and autoimmune disease
 XX PS Claim 9; Page 48-51; 85pp; French.
 XX CC The present sequence represents a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with
 CC abnormal gene expression, or promoters and regulators of the gene,
 CC particularly for diagnosis; for recombinant expression of the derived
 CC protein; as probes and primers for detection and amplification; and
 CC as antisense therapeutics. The tumour expressed protein is useful for
 CC raising specific antibodies and to screen agents that modulate its
 CC activity, bind to it or interact with it. These agents are potentially
 CC useful for treatment or prevention of diseases associated with abnormal
 CC expression/activity of the protein, particularly immunological diseases
 CC (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
 CC infections.
 XX SO Sequence 1013 AA;

Query Match 67.4%; Score 675; DB 22; Length 1013;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 975; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 MAEPGSHHLSARVGRTERIRIPRLWRLIWAAGTAFOYTOGCGPRLHACKSEHYEYETA 60
 DB 1 MAEPGSHHLSARVGRTERIRIPRLWRLIWAAGTAFOYTOGCGPRLHACKSEHYEYETA 60
 QY 61 CDSTGSRVAVVPHPTGCTSLPDPKGTSCFSNAGEFLDMKQSCPKCAEGRYSIGT 120
 DB 61 CDSTGSRVAVVPHPTGCTSLPDPKGTSCFSNAGEFLDMKQSCPKCAEGRYSIGT 120
 QY 121 GIRDEWDELPHGFASLSANMELDDSAESTGNTSSKVPKPRGDIYIANTDECTATLMYA 180
 DB 121 GIRDEWDELPHGFASLSANMELDDSAESTGNTSSKVPKPRGDIYIANTDECTATLMYA 180
 QY 181 VNLKSGGVNPEYYPDSIIIEFFVONDQCPNADDSRMKTEKMGHEFSVELNRANN 240
 DB 181 VNLKSGGVNPEYYPDSIIIEFFVONDQCPNADDSRMKTEKMGHEFSVELNRANN 240
 QY 241 VLYWRTAFSVWTKVPRKVLVNIATITGVAATSECFPCPKPGTYADKQSSFCPLCPANSY 300
 DB 241 VLYWRTAFSVWTKVPRKVLVNIATITGVAATSECFPCPKPGTYADKQSSFCPLCPANSY 300
 QY 301 SNKGTSTCHQCDPKYSEKSSCNVRACTDKDYFYTHACDANGETOLMYKAKPKIC 360
 DB 301 SNKGTSTCHQCDPKYSEKSSCNVRACTDKDYFYTHACDANGETOLMYKAKPKIC 360
 QY 361 SEDLEGAVKLPASGVKTHCPNPGFFKNNSTCOPCYGSYNSDCTRCAGTEPVG 420
 DB 361 SEDLEGAVKLPASGVKTHCPNPGFFKNNSTCOPCYGSYNSDCTRCAGTEPVG 420
 QY 421 FEYKMMNTLPTNMTETVLGGINFEYKMTGWEVADHITYAAGASDNDFMILLVLPQFR 480
 DB 421 FEYKMMNTLPTNMTETVLGGINFEYKMTGWEVADHITYAAGASDNDFMILLVLPQFR 480

DB 421 FEYKMMNTLPTNMTETVLGGINFEYKMTGWEVADHITYAAGASDNDFMILLVLPQFR 480
 QY 481 PPOSVADTENKEVARITFEETLCSVNCELYFWVGVNSRINTPEVTWKSCKGQSYTYI 540
 DB 481 PPOSVADTENKEVARITFEETLCSVNCELYFWVGVNSRINTPEVTWKSCKGQSYTYI 540
 QY 541 IEENTTSSTFAFORITTHESKRKYNDVAKIYSINTVNMNGVASYCRPCALASVGS 600
 DB 541 IEENTTSSTFAFORITTHESKRKYNDVAKIYSINTVNMNGVASYCRPCALASVGS 600
 QY 601 SCTSCPAGYIYDRDSGTCHSCPNTILKAHOPYGVQACVPCPGPTKNNKIHSLCYNDCTF 660
 DB 601 SCTSCPAGYIYDRDSGTCHSCPNTILKAHOPYGVQACVPCPGPTKNNKIHSLCYNDCTF 660
 QY 661 SRNTPRTFNYSALANTVTLAAGPSFTSKGLYFHHFTLSLGNQGRKMSVCTDNVTD 720
 DB 661 SRNTPRTFNYSALANTVTLAAGPSFTSKGLYFHHFTLSLGNQGRKMSVCTDNVTD 720
 QY 721 LRIBEGSGFSKSTIYAVCAVITPEVTVGYKAGVSSQPVSLARLIGVTTDMTLDGITS 780
 DB 721 LRIBEGSGFSKSTIYAVCAVITPEVTVGYKAGVSSQPVSLARLIGVTTDMTLDGITS 780
 QY 781 PAELFHELSLGIPIVIFPFRSNDVTQSCSGRSTTIRVRCSPKTVPGSLLPCTCSDGT 840
 DB 781 PAELFHELSLGIPIVIFPFRSNDVTQSCSGRSTTIRVRCSPKTVPGSLLPCTCSDGT 840
 QY 841 CDGCFHFLMESAAACPLCSVADYHAIVSSCVAGIQKTYVWREPKLCSGGISLPEQRYT 900
 DB 841 CDGCFHFLMESAAACPLCSVADYHAIVSSCVAGIQKTYVWREPKLCSGGISLPEQRYT 900
 QY 901 ICKTIDFWLKXGISAGCTTALLTVLTCYFPMKKNQKLEYKSKLWMAATLKDCLPADS 960
 DB 901 ICKTIDFWLKXGISAGCTTALLTVLTCYFPMKKNQKLEYKSKLWMAATLKDCLPADS 960
 QY 961 CAIMEGEDVEDDLIFTSK 978
 DB 961 CAIMEGEDVEDDLIFTSK 978

RESULT 6
 AAB83850
 ID AAB83850 standard; Protein; 911 AA.
 XX
 AC AAB83850;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Amino acid sequence of a human protein expressed in tumour cells.
 XX
 KW Tumour cell; immunological disease; autoimmune disease; cancer;
 XX
 OS Infection.
 XX
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX
 DR WPI; 2001-328651/34.
 XX
 DR N-PSDB; AAF89774.
 XX
 PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 PT identifying agents for treating tumours and autoimmune disease
 XX
 XX Claim 10; Page 60-63; 85pp; French.

XX The present sequence represents a human protein expressed in tumour cells. The polynucleotide is useful for screening cDNA/genomic DNA banks and for cloning isolated DNA, identifying mutant forms of the gene that encodes a human protein, where the mutations are associated with abnormal gene expression, or promoters and regulators of the gene, particularly for diagnosis; for recombinant expression of the derived protein; as probes and primers for detection and amplification; and as antisense therapeutics. The tumour expressed protein is useful for raising specific antibodies and to screen agents that modulate its activity, bind to it or interact with it. These agents are potentially useful for treatment or prevention of diseases associated with abnormal expression/activity of the protein, particularly immunological diseases (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic infections.

XX
 SO Sequence 911 AA;

Query Match 66.1%; Score 662; DB 22; Length 911;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 862; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MAEPGSHHLSARVGRTERIRIPRLMLLAGTAFOVOTGTELBACESEHYEYTA 60
 DB 1 MAEPGSHHLSARVGRTERIRIPRLMLLAGTAFOVOTGTELBACESEHYEYTA 60

QY 61 CDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFLDMKQSCPKPAERYSLGT 120
 DB 61 CDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFLDMKQSCPKPAERYSLGT 120

QY 121 GIRFDEWDELPHGFASLSANMELDLSAESTGNTSSKWPBGDYIAFNTDECTATMYA 180
 DB 121 GIRFDEWDELPHGFASLSANMELDLSAESTGNTSSKWPBGDYIAFNTDECTATMYA 180

QY 181 VNLKQSGTVNFEYYPDSIIIEFFVONDOCPNADSRMKTTEKGEFHSVELANGNN 240
 DB 181 VNLKQSGTVNFEYYPDSIIIEFFVONDOCPNADSRMKTTEKGEFHSVELANGNN 240

QY 241 VLVWRTAFSVWTVKVPVLRNIAITGVATSECPKQGTVDKQSSSCCKCPANSY 300
 DB 241 VLVWRTAFSVWTVKVPVLRNIAITGVATSECPKQGTVDKQSSSCCKCPANSY 300

QY 301 SNGGETSCHOCDDPKYSEKSSSCNVRPACTDKDYFYTHTAACDANGTOLMYKMAKPKIC 360
 DB 301 SNGGETSCHOCDDPKYSEKSSSCNVRPACTDKDYFYTHTAACDANGTOLMYKMAKPKIC 360

QY 361 SEDLEGAVKLPAAGVKTCHPCPNPGFKTNNSTOCPCPYGYSNGSDCTRCPAETEPAVG 420
 DB 361 SEDLEGAVKLPAAGVKTCHPCPNPGFKTNNSTOCPCPYGYSNGSDCTRCPAETEPAVG 420

QY 421 FEYKMWNTLPTNMTTSLSGINEFYKMTGMEVAGDHITAAAGSNDPMILTIVNGFR 480
 DB 421 FEYKMWNTLPTNMTTSLSGINEFYKMTGMEVAGDHITAAAGSNDPMILTIVNGFR 480

QY 481 PPOSVADTENKEXARITTFVETLCSVNCBLFYFVGVNSRTNTPVEFTWKSCKGOSTYI 540
 DB 481 PPOSVADTENKEXARITTFVETLCSVNCBLFYFVGVNSRTNTPVEFTWKSCKGOSTYI 540

QY 541 IERTTTSTFWAFORTTFHEASRKYNDVAKIYSINVTNNGVASYCRPCALASVGS 600
 DB 541 IERTTTSTFWAFORTTFHEASRKYNDVAKIYSINVTNNGVASYCRPCALASVGS 600

QY 601 SCTSCPAAGYIYDRSGTCHSCPNTILKAHOPVGOACVCPGPTKNNKHSHCYNDCTF 660
 DB 601 SCTSCPAAGYIYDRSGTCHSCPNTILKAHOPVGOACVCPGPTKNNKHSHCYNDCTF 660

QY 661 SRNPTPTFNFNFSALANTYTLAAGPSTSKGLYFHHFTLSLGNQGRKMSVCTDVTVD 720
 DB 661 SRNPTPTFNFNFSALANTYTLAAGPSTSKGLYFHHFTLSLGNQGRKMSVCTDVTVD 720

QY 721 LRIPBEGSSGSKITAYVCAVITPEVYTGKAGVSSOPVSLADRLIGVTTDMTLDGITS 780
 DB 721 LRIPBEGSSGSKITAYVCAVITPEVYTGKAGVSSOPVSLADRLIGVTTDMTLDGITS 780

QY 781 PAELFHESTIGIPDVIFFVRSNDVTOSSGSRSTTIRVRCSPQXTVPGSILLPCTGSDGT 840
 DB 781 PAELFHESTIGIPDVIFFVRSNDVTOSSGSRSTTIRVRCSPQXTVPGSILLPCTGSDGT 840

QY 841 CDGCFHFLMESAAACPLCSVADY 864
 DB 841 CDGCFHFLMESAAACPLCSVADY 864

RESULT 7
 AAB83851
 ID AAB83851 standard; Protein; 870 AA.
 XX
 AC AAB83851;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Amino acid sequence of a human protein expressed in tumour cells.
 XX
 KM Tumour cell; immunological disease; autoimmune disease; cancer;
 XX infection.
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeamin P, Bonnefoy J;
 XX
 DR WPI: 2001-328651/34.
 XX
 DR N-PSDB: AAB83851.
 XX
 PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 XX identifying agents for treating tumours and autoimmune disease
 XX
 PS Claim 10; Page 67-70; 85pp; French.
 XX
 CC The present sequence represents a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA, identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with
 CC abnormal gene expression, or promoters and regulators of the gene,
 CC particularly for diagnosis; for recombinant expression of the derived
 CC protein; as probes and primers for detection and amplification; and
 CC as antisense therapeutics. The tumour expressed protein is useful for
 CC raising specific antibodies and to screen agents that modulate its
 CC activity, bind to it or interact with it. These agents are potentially
 CC useful for treatment or prevention of diseases associated with abnormal
 CC expression/activity of the protein, particularly immunological diseases
 CC (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
 CC infections.
 CC
 SO Sequence 870 AA;

Query Match 62.0%; Score 621; DB 22; Length 870;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 821; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 42 TGBELHACKSEHYEYTAQDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFL 101
 DB 42 TGBELHACKSEHYEYTAQDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFL 101

QY 1 TGBELHACKSEHYEYTAQDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFL 60
 DB 1 TGBELHACKSEHYEYTAQDSTGSRWRAVPHPTPLCTSLPDVKGTECSFCNAGEFL 60

QY 102 DMKQSCPKCAEGRYSIGTIRFDEWDELPHGFASLSANMELDLSAESTGNTSSKWP 161
 DB 102 DMKQSCPKCAEGRYSIGTIRFDEWDELPHGFASLSANMELDLSAESTGNTSSKWP 161

QY 162 RGDIYAFNTDECTATLMYAVNLKSGSTVNFEEYYPDSSIIIEFFVQNDQCPNADSSRM 221
 DB 121 RGDIYASNTDSCITATLMYAVNLKSGSTVNFEEYYPDSSIIIEFFVQNDQCPNADSSRM 180
 QY 222 KTTKKGMEFHSVELNRGNVLYMTTASVMTKVKPKLVNRIATGYAAYSECPCKPG 281
 DB 181 KTTKKGMEFHSVELNRGNVLYMTTASVMTKVKPKLVNRIATGYAAYSECPCKPG 240
 QY 282 TYADKOGSSFPCLCPANSYNKGETSCHQCDPKYSEKSSSCNVRPACTDKDYFYHTA 341
 DB 241 TYADKOGSSFPCLCPANSYNKGETSCHQCDPKYSEKSSSCNVRPACTDKDYFYHTA 300
 QY 342 CDANGETOIMTKWAKPKICSEDLGAVLTPASGVKTHCPNPGFXTNNSTQCPYGS 401
 DB 301 CDANGETOIMTKWAKPKICSEDLGAVLTPASGVKTHCPNPGFXTNNSTQCPYGP 360
 QY 402 YSNGSDCTRCRCPAGTEPAVGFEXKMNNTLPJMETTVLSGINFEYKGMTGMEVAGDHITTA 461
 DB 361 YSNGSDCTRCRCPAGTEPAVGFEXKMNNTLPJMETTVLSGINFEYKGMTGMEVAGDHITTA 420
 QY 462 AGASDNDFMILTLLVVGFRPQSVADTENKEVARITFEVFTLCSVNCELYFMVGVNSRT 521
 DB 421 AGASDNDFMILTLLVVGFRPQSVADTENKEVARITFEVFTLCSVNCELYFMVGVNSRT 480
 QY 522 NTPVETWKGSKGKOSYTYIIENNTTSTTMAFQRTTFHASKRYNDVAKIYSINVTVM 581
 DB 481 NTPVETWKGSKGKOSYTYIIENNTTSTTMAFQRTTFHASKRYNDVAKIYSINVTVM 540
 QY 582 NGVASYCPCALAEADVSSCTSCPAAGYIIRDSGTCHSCPNTILKAHOPYGVQACVPC 641
 DB 541 NGVASYCPCALAEADVSSCTSCPAAGYIIRDSGTCHSCPNTILKAHOPYGVQACVPC 600
 QY 642 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYSALANTVTLAGSPFTSKGLKYFHHFTL 701
 DB 601 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYSALANTVTLAGSPFTSKGLKYFHHFTL 660
 QY 702 SLGCGNQRKMSVCTDNVTDLRIPEGESGFSKSIITAYVCOAVIIPPEVGYAGVSSQ 761
 DB 661 SLGCGNQRKMSVCTDNVTDLRIPEGESGFSKSIITAYVCOAVIIPPEVGYAGVSSQ 720
 QY 762 LADRLIGVTTMTLDGITSAPALFHLBSLGIIPDVIFFRSNDVYOSCGSGSTIRVCS 821
 DB 721 LADRLIGVTTMTLDGITSAPALFHLBSLGIIPDVIFFRSNDVYOSCGSGSTIRVCS 780
 QY 822 POKTVPSSLLPGTCSGTCDCGNCNHFHLMESAACPLCSVADY 864
 DB 781 POKTVPSSLLPGTCSGTCDCGNCNHFHLMESAACPLCSVADY 823
 RESULT 8
 AAY5972
 ID AAY5972 standard; Protein; 495 AA.
 AC AAY5972;
 DT 31-JAN-2000 (first entry)
 DE Human endometrium tumour EST encoded protein 32.
 KM Endometrium; human; tumour; cancer; anticancer; cytostatic; EST:
 treatment; uterine; gene therapy; expressed sequence tag.
 OS Homo sapiens.
 PN DE19817948-A1.
 PD 21-OCT-1999.
 PF 17-APR-1998; 98DE-1017948.
 PR 17-APR-1998; 98DE-1017948.
 XX

PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
 XX Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
 XX WPI; 1999-591957/51.
 DR N-PSDB; AAZ41991.
 PT New nucleic acid sequences expressed in uterine cancer tissues, and
 PT derived polypeptides, for treatment of uterine and endometrial cancer
 PT and identification of therapeutic agents -
 PS Claim 23; Page 287; 444pp; German.
 XX
 CC This invention describes novel human nucleic acid (cDNA) sequences (A),
 CC that are highly expressed in uterine tumour tissue and which have
 CC anticancer and cytostatic activity. (A) are used (i) for recombinant
 CC expression of polypeptides (B) and (ii) to isolate complete genes. (B)
 CC are used (i) to identify agents suitable for treatment of uterine or
 CC endometrial cancer; (ii) directly for treating these forms of cancer
 CC (including expression from gene therapy vectors) and (iii) for
 CC generation of specific antibodies. (A) are identified by assembling ESTs
 CC (expressed sequence tags) from a particular tissue type before comparison
 CC of expression patterns. This allows a significantly longer fragment of
 CC the gene to be revealed, so should reduce the number of failures
 CC associated with the fact that ESTs from different libraries may represent
 CC different parts of the same unknown gene, distorting the estimated
 CC frequency of occurrence in a particular tissue. AAY5941-Y60328 represent
 CC protein fragments encoded by the human endometrium tumour cDNA library
 CC derived EST fragments represented in AAZ41981-242121.
 XX
 SQ Sequence 495 AA;
 Query Match 46.0%; Score 460; DB 20; Length 495;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 460; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 519 SRTNTPVETWKGSKGKOSYTYIIENNTTSTTMAFQRTTFHASKRYNDVAKIYSINVT 578
 DB 1 SRTNTPVETWKGSKGKOSYTYIIENNTTSTTMAFQRTTFHASKRYNDVAKIYSINVT 60
 QY 579 NVNMGVASYCPCALAEADVSSCTSCPAAGYIIRDSGTCHSCPNTILKAHOPYGVQAC 638
 DB 61 NVNMGVASYCPCALAEADVSSCTSCPAAGYIIRDSGTCHSCPNTILKAHOPYGVQAC 120
 QY 639 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYSALANTVTLAGSPFTSKGLKYFHH 698
 DB 121 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYSALANTVTLAGSPFTSKGLKYFHH 180
 QY 699 FTLGCGNQRKMSVCTDNVTDLRIPEGESGFSKSIITAYVCOAVIIPPEVGYAGVSSQ 758
 DB 181 FTLGCGNQRKMSVCTDNVTDLRIPEGESGFSKSIITAYVCOAVIIPPEVGYAGVSSQ 240
 QY 759 PVSILADRLIGVTTMTLDGITSAPALFHLBSLGIIPDVIFFRSNDVYOSCGSGSTIRV 818
 DB 241 PVSILADRLIGVTTMTLDGITSAPALFHLBSLGIIPDVIFFRSNDVYOSCGSGSTIRV 300
 QY 819 RCPSPQKTVPGSSLLPGTCSGTCDCGNCNHFHLMESAACPLCSVADYHAIYSSCVAGIOKT 878
 DB 301 RCPSPQKTVPGSSLLPGTCSGTCDCGNCNHFHLMESAACPLCSVADYHAIYSSCVAGIOKT 360
 QY 879 TYVWREPTLCSGGISLPEORTTICKTIDFWLKVGISAGTCATLLTYLTCFWMKQKLE 938
 DB 361 TYVWREPTLCSGGISLPEORTTICKTIDFWLKVGISAGTCATLLTYLTCFWMKQKLE 420
 QY 939 YKYSKLVNNTATLKDCLDLPADSCAIMEGEVEDDLIFTSK 978
 DB 421 YKYSKLVNNTATLKDCLDLPADSCAIMEGEVEDDLIFTSK 460
 RESULT 9
 AAB83853
 ID AAB83853 standard; Protein; 383 AA.

AC	AAB63853;
XX	
DT	23-JUL-2001 (first entry)
XX	
DE	Amino acid sequence of a human protein expressed in tumour cells.
XX	
KW	Tumour cell; immunological disease; autoimmune disease; cancer; infection.
XX	
OS	Homo sapiens.
XX	
PN	WO200131003-A1.
XX	
PF	30-OCT-2000; 2000WO-FR03032.
XX	
PR	29-OCT-1999; 99FR-0013629.
XX	
PA	(FABR) FABRE MEDICAMENT SA PIERRE.
XX	
PI	Delaeste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX	
DR	WPI: 2001-328651/34.
DR	N-PDSB; AAF89777.
XX	
PT	New nucleic acid, expressed in tumours and lymphoid tissue is useful for identifying agents for treating tumours and autoimmune disease -
XX	
P5	Claim 10; Page 74-75; 85pp; French.
CC	The present sequence represents a human protein expressed in tumour cells. The polynucleotide is useful for screening cDNA/genomic DNA banks and for cloning isolated DNA; identifying mutant forms of the gene that encodes a human protein, where the mutations are associated with abnormal gene expression, or promoters and regulators of the gene, particularly for diagnosis; for recombinant expression of the derived protein; as probes and primers for detection and amplification; and as antisense therapeutics. The tumour expressed protein is useful for raising specific antibodies and to screen agents that modulate its activity, bind to it or interact with it. These agents are potentially useful for treatment or prevention of diseases associated with abnormal expression/activity of the protein, particularly immunological diseases (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic infections.
CC	
CC	
CC	
Sequence	383 AA;
Query Match	24.9%; Score 249; DB 22; Length 383;
Best Local Similarity	99.7%; Pred. No. 1.5e-253;
Matches 349; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
OY	169 NNDCEATITMVAVNLKQSTNNEFYYPSSIIIFEFVNDDCOPPADSRMKTKTEKW 228
DB	34 NIDCEAITLMAVANLNKQSTVANFEYYPSIIIFEFVNDDCOPPADSRMKTKTEKW 93
OY	229 BEHSEVLNRGNVVLYWRITAFSVMTKVPRVLVRNIATGVAVTSECFCKPGTYADKOG 288
DB	94 BEHSEVLNRGNVVLYWRITAFSVMTKVPRVLVRNIATGVAVTSECFCKPGTYADKOG 153
OY	289 SSFCFLCPANISYNKETISCHODCDPKYSSEKSSSCNVAPACTDKDYFTHTACDANGET 348
DB	154 SSFCFLCPANISYNKETISCHODCDPKYSSEKSSSCNVAPACTDKDYFTHTACDANGET 213
OY	349 QLMYMAKPRTISEDLLEGVVKLPASGVTHPCPNDGFPTKTNNSTTCPPSYSGNSGC 408
DB	214 QLMYMAKPRTISEDLLEGVVKLPASGVTHPCPNDGFPTKTNNSTTCPPSYSGNSGC 273
OY	409 TRCPAGTEBAVFEEYKMNTTLPTNNETTLYLSGINEFYKMTGMEVAGDIITYAAGASDND 468
DB	274 TRCPAGTEBAVFEEYKMNTTLPTNNETTLYLSGINEFYKMTGMEVAGDIITYAAGASDND 333
OY	469 FMITLVIVDGFRPPOSVMADTENKEVARITTFVEYLCSVNCELYPMGVNA 518

[illegible]

QY 121 GIRDENDELPHGASASANNELDDSAESTGCTSKVPRGRDYIAFNTDECTATLMA 180
 121 GIRDENDELPHGASASANNELDDSAESTGCTSKVPRGRDYIAFNTDECTATLMA 180
 QY 181 VNLKSGTAVNEFYYPDSIIIFEPFVNDQCOPNADSRMKTTEKGEFHSVELNRGN 240
 181 VNLKSGTAVNEFYYPDSIIIFEPFVNDQCOPNADSRMKTTEKGEFHSVELNRGN 240
 QY 241 VLYMRTAFSVWTVKPVLRNIAITGVATSECFPGKPGTVADKQSSFCXCLPANSY 300
 241 VLYMRTAFSVWTVKPVLRNIAITGVATSECFPGKPGTVADKQSSFCXCLPANSY 300
 QY 301 SNKGETSCHQCDPKYS 317
 301 SNKGETSCHQCDPKYS 317
 Db 301 SNKGETSCHQCDPKYS 317

RESULT 11
 AAB53442 standard; Protein; 208 AA.
 ID AAB53442
 AC AAB53442;
 DT 09-MAR-2001 (first entry)
 DE Human colon cancer antigen protein sequence SEQ ID NO:982.
 XX Human; colon cancer; colon cancer antigen; diagnosis; detection;
 KM identification; cytostatic; cardioactive; neuroprotective; vulnery;
 KM immunomodulatory; muscular; gynaecological; gastrointestinal;
 KM nephrotoxic; anti-infective; antibacterial; gene therapy; wound;
 KM neural disorder; immune system disorder; muscular disorder;
 KM reproductive disorder; gastrointestinal disorder; renal disorder;
 KM infectious disease; cardiovascular disorder.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO20005351-A1.
 PN 21-SEP-2000.
 PD 08-MAR-2000; 2000MO-US05883.
 PF 12-MAR-1999; 99US-0124270.
 PR (HUMA-) HUMAN GENOME SCI INC.
 PA Rosen CA, Ruben SM;
 XX WPI; 2000-587534/55.
 DR N-PSDB; AAC98199.
 XX Colonic cancer associated gene sequences, referred to as colon cancer
 PT antigens, useful for the treatment, prevention, and diagnosis of colon
 PT disorders such as colon cancer -
 PS Claim 11; Page 1556; 2104pp; English.
 XX AAC97991 to AAC98763 encode the human colon cancer associated proteins,
 CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
 CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
 CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
 CC vulnery, nephrotoxic, anti-infective and antibacterial activities, and
 CC can be used in gene therapy. The colon cancer antigen polynucleotides,
 CC proteins and antibodies to the proteins are useful for the prevention,
 CC treatment and diagnosis of colon disorders, such as colon cancer. The
 CC polynucleotides may be used in diagnostics and research, such as for
 CC chromosome identification, and as hybridisation probes. The proteins
 CC may also be used to prevent diseases such as neural disorders, immune
 CC system disorders, muscular disorders, reproductive disorders, immune
 CC gastrointestinal disorders, wounds, renal disorders, infectious
 CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and

CC AAB54007 represent sequences used in the exemplification of the present
 CC invention.
 XX Sequence 208 AA;
 SQ Query Match 15.0%; Score 150; DB 21; Length 208;
 Best Local Similarity 100.0%; Pred. No. 2,7e-149;
 Matches 150; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 690 SKGLKYPFHFTSLSCGQGRKMSVCTDNVTDLRIPESGFSKSIYVCOAVIIPPEVT 749
 690 SKGLKYPFHFTSLSCGQGRKMSVCTDNVTDLRIPESGFSKSIYVCOAVIIPPEVT 749
 Db 30 SKGLKYPFHFTSLSCGQGRKMSVCTDNVTDLRIPESGFSKSIYVCOAVIIPPEVT 89
 30 SKGLKYPFHFTSLSCGQGRKMSVCTDNVTDLRIPESGFSKSIYVCOAVIIPPEVT 89
 QY 750 GYKAGVSSQPVSLADRLIGVTTDITSPALFHLSELGIPDVIFFYRSNDVTQSCS 809
 750 GYKAGVSSQPVSLADRLIGVTTDITSPALFHLSELGIPDVIFFYRSNDVTQSCS 809
 Db 90 GYKAGVSSQPVSLADRLIGVTTDITSPALFHLSELGIPDVIFFYRSNDVTQSCS 149
 90 GYKAGVSSQPVSLADRLIGVTTDITSPALFHLSELGIPDVIFFYRSNDVTQSCS 149
 QY 810 SGRSTTIRVRCSPQKTVPGSLLPGTCSG 839
 810 SGRSTTIRVRCSPQKTVPGSLLPGTCSG 839
 Db 150 SGRSTTIRVRCSPQKTVPGSLLPGTCSG 179

RESULT 12
 AAB83849 standard; peptide; 147 AA.
 ID AAB83849
 AC AAB83849;
 DT 23-JUL-2001 (first entry)
 DE Peptide fragment of a human protein expressed in tumour cells.
 XX Tumour cell; immunological disease; autoimmune disease; cancer;
 KM infection.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO200131003-A1.
 PN 03-MAY-2001.
 PD 30-OCT-2000; 2000MO-FR03032.
 PF 29-OCT-1999; 99FR-0013629.
 PR (FABR) FABRE MEDICAMENT SA PIERRE.
 PA Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX WPI; 2001-328651/34.
 DR N-PSDB; AAF9769.
 XX New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 PT identifying agents for treating tumours and autoimmune disease -
 PS Claim 10; Page 54-55; 85pp; French.
 XX AAB83846-49 represent fragments of a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with abnormal
 CC gene expression, or promoters and regulators of the gene, particularly
 CC for diagnosis; for recombinant expression of the derived protein; as
 CC probes and primers for detection and amplification; and as antisense
 CC therapeutics. The tumour expressed protein is useful for raising specific
 CC antibodies and to screen agents that modulate its activity, bind to it
 CC or interact with it. These agents are potentially useful for treatment
 CC or prevention of diseases associated with abnormal expression/activity
 CC of the protein, particularly immunological diseases (autoimmune diseases
 CC and cancer) or viral, bacterial, fungal or parasitic infections.
 XX Sequence 147 AA;

Query Match 14.7%; Score 147; DB 22; Length 147;
 Best Local Similarity 100.0%; Pred. No. 2.9e-146;
 Matches 147; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 CYNDCFTSRNTPTRTFNYSALANTYTLAGSGFTSKGLKTHHTLSICNGGRKMSV 713
 DB 1 CYNDCFTSRNTPTRTFNYSALANTYTLAGSGFTSKGLKTHHTLSICNGGRKMSV 60

QY 714 CTNNVVDLRIPESGSGSKITAYVCOAVIPELVGYKAGVSGPSVSLADRLIGVTTDM 773
 DB 61 CTNNVVDLRIPESGSGSKITAYVCOAVIPELVGYKAGVSGPSVSLADRLIGVTTDM 120

QY 774 TLDGITSFALFHLSEIGIPDVIFPYR 800
 DB 121 TLDGITSFALFHLSEIGIPDVIFPYR 147

RESULT 13
 AAB83852 standard; Protein; 209 AA.
 AC AAB83852;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Amino acid sequence of a human protein expressed in tumour cells.
 XX
 KM Tumour cell; immunological disease; autoimmune disease; cancer;
 XX infection.
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX
 DR WPI; 2001-328651/34.
 XX
 PT N-PSDB; AAF89776.
 XX
 PS New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 PT identifying agents for treating tumours and autoimmune disease -
 XX
 PS Claim 10; Page 71-72; 85pp; French.
 XX
 CC The present sequence represents a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with
 CC abnormal gene expression; or promoters and regulators of the gene,
 CC particularly for diagnosis; for recombinant expression of the gene,
 CC as antisense therapeutics. The tumour expressed protein is useful for
 CC raising specific antibodies and to screen agents that modulate its
 CC activity, bind to it or interact with it. These agents are potentially
 CC useful for treatment or prevention of diseases associated with abnormal
 CC expression/activity of the protein, particularly immunological diseases
 CC (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
 CC infections.
 CC
 XX Sequence 209 AA;

Query Match 11.7%; Score 117; DB 22; Length 209;
 Best Local Similarity 100.0%; Pred. No. 1.8e-114;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 YSNGSDCTRCRPAEPVAVGEYKMMNTLPTMERTTVLSGINEFKGWTGMEVAGDHTYTA 461
 DB 93 YSNGSDCTRCRPAEPVAVGEYKMMNTLPTMERTTVLSGINEFKGWTGMEVAGDHTYTA 152

QY 462 AGASNDPMILTLVVPGRPPQSVADTENKEVARITFEVETLCSVACELVFMVGNV 518
 DB 153 AGASNDPMILTLVVPGRPPQSVADTENKEVARITFEVETLCSVACELVFMVGNV 209

RESULT 14
 AAB26180 standard; Protein; 105 AA.
 ID AAB26180
 XX
 AC AAB26180;
 XX
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein #2.
 XX
 KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX
 OS Homo sapiens.
 XX
 PN WO200058460-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 XX
 PR 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Bruck CEM, Caesart J, Coche T, Vinals De Bassols YC;
 XX
 DR WPI; 2000-664923/64.
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Disclosure; Page 56; 68pp; English.
 XX
 CC The present sequence comprises part of the human CASB619 protein sequence
 CC derived from an EST. The CASB619 protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The invention provides a number of
 CC epitopes derived from the protein which can be used as immunogens.
 CC
 XX Sequence 105 AA;

Query Match 9.6%; Score 96; DB 21; Length 105;
 Best Local Similarity 100.0%; Pred. No. 1.4e-92;
 Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 864 YHIVSSCVAGIGIKTYTWAEPEKLCGGGSLPQRYTICKTIDFWKXGISACTTAIIL 923
 DB 1 YHIVSSCVAGIGIKTYTWAEPEKLCGGGSLPQRYTICKTIDFWKXGISACTTAIIL 60

QY 924 TVLTCYFMKNGKLEKYKSLVNNATLKDCLDLPAD 959
 DB 61 TVLTCYFMKNGKLEKYKSLVNNATLKDCLDLPAD 96

RESULT 15
 AAB83847 standard; peptide; 56 AA.
 ID AAB83847
 XX

AC AAB83847;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Peptide fragment of a human protein expressed in tumour cells.
 XX
 KW Tumour cell; immunological disease; autoimmune disease; cancer;
 XX infection.
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX WPI; 2001-328651/34.
 DR N-PSDB; AAF89767.
 XX
 PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 XX identifying agents for treating tumours and autoimmune disease
 PS Claim 10; Page 52-53; 85pp; French.
 XX
 CC AAB83846-49 represent fragments of a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with abnormal
 CC gene expression, or promoters and regulators of the gene, particularly
 CC for diagnosis; for recombinant expression of the derived protein; as
 CC probes and primers for detection and amplification; and as antisense
 CC therapeutics. The tumour expressed protein is useful for raising specific
 CC antibodies and to screen agents that modulate its activity, bind to it
 CC or interact with it. These agents are potentially useful for treatment
 CC of the protein, particularly immunological diseases (autoimmune diseases
 CC and cancer) or viral, bacterial, fungal or parasitic infections.
 CC
 SQ Sequence 56 AA;
 XX
 XX
 Query Match 5.6%; Score 56; DB 22; Length 56;
 Best Local Similarity 100.0%; Pred. No. 1.4e-50;
 Matches 56; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 304 GETSCHQCDPDKYSEKSSSCNVRPACTDKDYFYTHACDANGETQLMYKAKKPKI 359
 DB 1 GETSCHQCDPDKYSEKSSSCNVRPACTDKDYFYTHACDANGETQLMYKAKKPKI 56
 XX
 RESULT 16
 AAB83848
 ID AAB83848 standard; peptide; 52 AA.
 XX
 AC AAB83848;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Peptide fragment of a human protein expressed in tumour cells.
 XX
 KW Tumour cell; immunological disease; autoimmune disease; cancer;
 XX infection.
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX

PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX WPI; 2001-328651/34.
 DR N-PSDB; AAF89768.
 XX
 PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 XX identifying agents for treating tumours and autoimmune disease
 PS Claim 10; Page 53; 85pp; French.
 XX
 CC AAB83846-49 represent fragments of a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with abnormal
 CC gene expression, or promoters and regulators of the gene, particularly
 CC for diagnosis; for recombinant expression of the derived protein; as
 CC probes and primers for detection and amplification; and as antisense
 CC therapeutics. The tumour expressed protein is useful for raising specific
 CC antibodies and to screen agents that modulate its activity, bind to it
 CC or interact with it. These agents are potentially useful for treatment
 CC of the protein, particularly immunological diseases (autoimmune diseases
 CC and cancer) or viral, bacterial, fungal or parasitic infections.
 CC
 SQ Sequence 52 AA;
 XX
 XX
 Query Match 5.2%; Score 52; DB 22; Length 52;
 Best Local Similarity 100.0%; Pred. No. 2.1e-46;
 Matches 52; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 472 LTLVPGFRPPQSVADTENKEVARITFVFETLCSVNCGLYFMVGNSRINT 523
 DB 1 LTLVPGFRPPQSVADTENKEVARITFVFETLCSVNCGLYFMVGNSRINT 52
 XX
 RESULT 17
 AAB83846
 ID AAB83846 standard; peptide; 45 AA.
 XX
 AC AAB83846;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Peptide fragment of a human protein expressed in tumour cells.
 XX
 KW Tumour cell; immunological disease; autoimmune disease; cancer;
 XX infection.
 OS Homo sapiens.
 XX
 PN WO200131003-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 30-OCT-2000; 2000WO-FR03032.
 XX
 PR 29-OCT-1999; 99FR-0013629.
 XX
 PA (FABR) FABRE MEDICAMENT SA PIERRE.
 XX
 PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
 XX WPI; 2001-328651/34.
 DR N-PSDB; AAF89766.
 XX

PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
 PT identifying agents for treating tumours and autoimmune disease -
 PS Claim 10; Page 52; 85pp; French.
 CC AAB83846-49 represent fragments of a human protein expressed in tumour
 CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
 CC and for cloning isolated DNA; identifying mutant forms of the gene that
 CC encodes a human protein, where the mutations are associated with abnormal
 CC gene expression, or promoters and regulators of the gene, particularly
 CC for diagnosis; for recombinant expression of the derived protein; as
 CC probes and primers for detection and amplification; and as antisense
 CC therapeutics. The tumour expressed protein is useful for raising specific
 CC antibodies and to screen agents that modulate its activity, bind to it
 CC or interact with it. These agents are potentially useful for treatment
 CC or prevention of diseases associated with abnormal expression/activity
 CC of the protein, particularly immunological diseases (autoimmune diseases
 CC and cancer) or viral, bacterial, fungal or parasitic infections.
 SQ Sequence 45 AA;
 Query Match 4.5%; Score 45; DB 22; Length 45;
 Best Local Similarity 100.0%; Pred. No. 4.5e-39;
 Matches 45; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAEPGSHHLSARVGRTERRIPRLMRLMAGTAFOVGTGPE 45
 Db 1 MAEPGSHHLSARVGRTERRIPRLMRLMAGTAFOVGTGPE 45
 RESULT 18
 ID AAY12274 standard; Protein; 150 AA.
 AC AAY12274;
 XX 17-JUN-1999 (first entry)
 DT 17-JUN-1999 (first entry)
 DE Human 5' EST secreted protein SEQ ID NO:305.
 XX Human; secreted protein; EST; expressed sequence tag; diagnosis;
 KM forensic; gene therapy; chromosome mapping; signal peptide;
 KM upstream regulatory sequence; cytokine activity; cell proliferation;
 KM differentiation; haematopoiesis regulation; tissue growth regulation;
 KM reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
 KM thrombolytic; anti-inflammatory; tumour inhibition.
 OS Homo sapiens.
 XX WO906548-A2.
 PN 11-FEB-1999.
 PD 31-JUL-1998; 98WO-1B01222.
 PF 01-AUG-1997; 97US-0905135.
 PR (GENSET) GENSET.
 PA Duclert A, Dumas Milne Edwards J, Lacroix B;
 PI WPI; 1999-153778/13.
 DR N-PSDB; AAX41107.
 CC New nucleic acids encoding human secreted proteins - obtained from
 PT cDNA libraries prepared from e.g. liver, ovary, brain, prostate,
 PT kidney, lung, umbilical cord, placenta and colon tissue
 XX Claim 27; Page 655-656; 824pp; English.
 PS AAX41094 to AAX41347 represent 5' expressed sequence tags (ESTs) for
 CC human secreted proteins, and encode the proteins given in AAY12261 to
 CC AAY12514, respectively. The proteins given represent the signal peptide

CC and an N-terminal fragment of a secreted protein. The nucleic acid
 CC sequences can be used for producing secreted human gene products. They
 CC can also be used to develop products for diagnosis and therapy. The
 CC proteins obtained may have cytokine activity, cell
 CC proliferation/differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, reproductive hormone
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter
 CC sequences. The nucleic acids encoding the signal peptide can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell.
 SQ Sequence 150 AA;
 Query Match 3.8%; Score 38; DB 20; Length 150;
 Best Local Similarity 100.0%; Pred. No. 3.3e-31;
 Matches 38; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAEPGSHHLSARVGRTERRIPRLMRLMAGTAFOV 38
 Db 1 MAEPGSHHLSARVGRTERRIPRLMRLMAGTAFOV 38
 RESULT 19
 ID AAB70256 standard; Protein; 1027 AA.
 AC AAB70256;
 XX 10-MAY-2001 (first entry)
 DT 10-MAY-2001 (first entry)
 DE TR16-long receptor protein.
 XX TR16 receptor; tumour necrosis factor receptor superfamily;
 KM apoptosis; inflammatory; cancer; immune; neurodegenerative.
 OS Unidentified.
 XX WO200112671-A1.
 PN 22-FEB-2001.
 PD 10-AUG-2000; 2000WO-US21885.
 PF 12-AUG-1999; 99US-0148348.
 PR 13-AUG-1999; 99US-0148683.
 PR 13-AUG-1999; 99US-0148870.
 PR 16-AUG-1999; 99US-0148758.
 PR 17-AUG-1999; 99US-0149181.
 PR 18-AUG-1999; 99US-0149453.
 PR 19-AUG-1999; 99US-0149498.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Ruben SM, Young PE, Baker KP;
 PI WPI; 2001-138754/14.
 DR New nucleic acid molecule encoding a TR16 tumor necrosis factor
 PT receptor polypeptide, useful for the diagnosis and treatment of cancer,
 PT autoimmune disorders and cardiovascular diseases -
 PS Disclosure; Fig 4; 286pp; English.
 CC The present invention relates to a TR16 receptor (tumour necrosis
 CC factor receptor superfamily). The invention is useful treating
 CC diseases and disorders associated with the inhibited or increased
 CC apoptosis. In particular inflammatory diseases, cancers, immune and
 CC neurodegenerative disorders may be treated.

SQ Sequence 1027 AA;

Query Match 2.1%; Score 21; DB 22; Length 1027;

Best Local Similarity 100.0%; Pred. No. 1.6e-12; Mismatches 0; Gaps 0;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 926 LTCYFMKKNQLEKYKSLVM 946

DB 943 LTCYFMKKNQLEKYKSLVM 963

RESULT 20

AAB48372

ID AAB48372 standard; Protein; 411 AA.

XX AAB48372;

AC AAB48372;

XX 20-APR-2001 (first entry)

XX Human SEC5 protein sequence (clone ID 1795045.0.61).

XX SEC5; cytosolic; gynecological; gene therapy; screening assay; human;

XX SEC5; chromosomal mapping; forensic biology; cell proliferation; cancer;

XX cell differentiation; immune associated disorder; gestational disease.

XX Homo sapiens.

XX WO200078802-A2.

XX 28-DEC-2000.

XX 23-JUN-2000; 2000WO-US17328.

XX 23-JUN-1999; 99US-0140584.

XX 20-JUL-1999; 99US-0144722.

XX 16-SEP-1999; 99US-0154520.

XX 22-JUN-2000; 2000US-0604286.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Fernandes E, Vernet C, Yang M, Boldog FL;

XX Hermann JL;

XX WPI; 2001-071385/08.

XX N-PSDB; AAC84886.

XX Polynucleotides encoding SECX proteins useful for treating disease

XX characterized by an aberrant level of cell proliferation and/or

XX differentiation like cancer or immune associated disorders -

XX Claim 1; Fig 6; 132pp; English.

XX The invention relates to human SECX polypeptides and polynucleotides

XX encoding them. The SECX polypeptides can be expressed by standard

XX recombinant methodology. The SECX polypeptides are useful for treating

XX or preventing a SECX-associated disorder. The invention is useful in

XX screening assays; detection assays (e.g. chromosomal mapping, cell and

XX tissue typing, forensic biology); predictive medicine (diagnostic assays,

XX prognostic assays, monitoring clinical trials, and pharmacogenomics); and

XX methods of treatment (e.g. therapeutic and prophylactic), especially

XX disorders characterized by aberrant cell proliferation and/or

XX differentiation like cancer or immune associated disorders or gestational

XX disease. The present sequence represents a SEC5 protein.

XX Sequence 411 AA;

SQ Query Match 1.5%; Score 15; DB 22; Length 411;

Best Local Similarity 100.0%; Pred. No. 1.5e-06; Mismatches 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 268 GVAATSECFPCPKPGT 282

DB 116 GVAATSECFPCPKPGT 130

RESULT 21

AAB48377

ID AAB48377 standard; Protein; 464 AA.

XX AAB48377;

XX 20-APR-2001 (first entry)

XX Human SEC10 protein sequence (clone ID 1795045.0.77).

XX SEC10; cytosolic; gynecological; gene therapy; screening assay; human;

XX SEC10; chromosomal mapping; forensic biology; cell proliferation; cancer;

XX cell differentiation; immune associated disorder; gestational disease.

XX Homo sapiens.

XX WO200078802-A2.

XX 28-DEC-2000.

XX 23-JUN-2000; 2000WO-US17328.

XX 23-JUN-1999; 99US-0140584.

XX 20-JUL-1999; 99US-0144722.

XX 16-SEP-1999; 99US-0154520.

XX 22-JUN-2000; 2000US-0604286.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Fernandes E, Vernet C, Yang M, Boldog FL;

XX Hermann JL;

XX WPI; 2001-071385/08.

XX N-PSDB; AAC84891.

XX Polynucleotides encoding SECX proteins useful for treating disease

XX characterized by an aberrant level of cell proliferation and/or

XX differentiation like cancer or immune associated disorders -

XX Claim 1; Fig 10; 132pp; English.

XX The invention relates to human SECX polypeptides and polynucleotides

XX encoding them. The SECX polypeptides can be expressed by standard

XX recombinant methodology. The SECX polypeptides are useful for treating

XX or preventing a SECX-associated disorder. The invention is useful in

XX screening assays; detection assays (e.g. chromosomal mapping, cell and

XX tissue typing, forensic biology); predictive medicine (diagnostic assays,

XX prognostic assays, monitoring clinical trials, and pharmacogenomics); and

XX disorders characterized by aberrant cell proliferation and/or

XX differentiation like cancer or immune associated disorders or gestational

XX disease. The present sequence represents a SEC10 protein.

XX Sequence 464 AA;

SQ Query Match 1.5%; Score 15; DB 22; Length 464;

Best Local Similarity 100.0%; Pred. No. 1.7e-06; Mismatches 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 268 GVAATSECFPCPKPGT 282

DB 169 GVAATSECFPCPKPGT 183

RESULT 22

AAB70255

ID AAB70255 standard; Protein; 963 AA.

XX AAB70255;

AC AAB70255;

XX 10-MAY-2001 (first entry)

XX TR16-short receptor protein.
 DE TR16 receptor; tumour necrosis factor receptor superfamily;
 KW apoptosis; inflammatory; cancer; immune; neurodegenerative.
 XX
 OS Unidentified.
 XX
 PN WO200112671-A1.
 PD
 XX 22-FEB-2001.
 XX
 PF 10-AUG-2000; 2000WO-US21885.
 XX
 PR 12-AUG-1999; 99US-0148348.
 PR 13-AUG-1999; 99US-0148683.
 PR 13-AUG-1999; 99US-0148870.
 PR 16-AUG-1999; 99US-0148758.
 PR 17-AUG-1999; 99US-0149181.
 PR 18-AUG-1999; 99US-0149453.
 PR 19-AUG-1999; 99US-0149498.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ruben SM, Young PE, Baker KP;
 XX WPI; 2001-138754/14.
 DR
 XX
 PT New nucleic acid molecule encoding a TR16 tumor necrosis factor
 PT receptor polypeptide, useful for the diagnosis and treatment of cancer,
 PT autoimmune disorders and cardiovascular diseases -
 XX
 PS Claim 1; Fig 1; 286bp; English.
 XX
 CC The present invention relates to a TR16 receptor (tumour necrosis
 CC factor receptor superfamily). The invention is useful for treating
 CC diseases and disorders associated with the inhibited or increased
 CC apoptosis. In particular inflammatory diseases, cancers, immune and
 CC neurodegenerative disorders may be treated.
 XX
 SQ Sequence 963 AA;
 XX
 Query Match 1.5%; Score 15; DB 22; Length 963;
 Best Local Similarity 100.0%; Pred. No. 3.3e-06;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 268 GVAVTSECPCKPQT 282
 DB 283 GVAVTSECPCKPQT 297
 XX
 RESULT 23
 ABB39681
 ID ABB39681 standard; Peptide; 50 AA.
 XX
 AC ABB39681;
 XX
 DT 04-FEB-2002 (first entry)
 XX
 DE Peptide #7187 encoded by human foetal liver single exon probe.
 XX
 KW Human; foetal liver; gene expression; single exon nucleic acid probe.
 XX
 OS Homo sapiens.
 XX
 PN WO200157277-A2.
 PD
 XX 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US00669.
 XX
 PR 04-FEB-2000; 2000US-0180312.
 PR 26-MAY-2000; 2000US-0207456.

PR 30-JUN-2000; 2000US-0608408.
 PR 03-AUG-2000; 2000US-0632366.
 PR 21-SEP-2000; 2000US-0234687.
 PR 27-SEP-2000; 2000US-0236359.
 PR 04-OCT-2000; 2000GB-0024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WPI; 2001-483447/52.
 DR
 XX
 PT Human genome-derived single exon nucleic acid probes useful for
 PT analyzing gene expression in human fetal liver -
 XX
 PS Claim 27; SEQ ID NO 32316; 639pp + sequence listing; English.
 XX
 CC The invention relates to a single exon nucleic acid probe for
 CC measuring human gene expression in a sample derived from human foetal
 CC liver. The single exon nucleic acid probes may be used for predicting,
 CC measuring and displaying gene expression in samples derived from human
 CC fetal liver. The present sequence is a peptide encoded by a single exon
 CC nucleic acid probe of the invention.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 50 AA;
 XX
 Query Match 1.4%; Score 14; DB 22; Length 50;
 Best Local Similarity 100.0%; Pred. No. 2.6e-06;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 955 LPADSCAIMEGED 968
 DB 19 LPADSCAIMEGED 32
 XX
 RESULT 24
 ABB24346
 ID ABB24346 standard; Protein; 50 AA.
 XX
 AC ABB24346;
 XX
 DT 23-JAN-2002 (first entry)
 XX
 DE Protein #6345 encoded by probe for measuring heart cell gene expression.
 XX
 KW Human; gene expression; heart; microarray; vascular system;
 KW cardiovascular disease; hypertension; cardiac arrhythmia;
 KW congenital heart disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200157274-A2.
 PD
 XX 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US00666.
 XX
 PR 04-FEB-2000; 2000US-0180312.
 PR 26-MAY-2000; 2000US-0207456.
 PR 30-JUN-2000; 2000US-0608408.
 PR 03-AUG-2000; 2000US-0632366.
 PR 21-SEP-2000; 2000US-0234687.
 PR 27-SEP-2000; 2000US-0236359.
 PR 04-OCT-2000; 2000GB-0024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WPI; 2001-488899/53.

XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts -
XX
PS Claim 15; SEQ ID No 26116; 530bp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 50 AA;
XX
Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 955 LPADSCAIMEGED 968
DB 19 LPADSCAIMEGED 32
XX
RESULT 25
AAM60397
ID AAM60397 standard; Protein; 50 AA.
XX
XX AAM60397;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 32502.
XX
XX Human; brain expressed exon; gene expression analysis; probe;
XX microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
XX epilepsy; cancer.
XX
XX Homo sapiens.
XX
XX MO200157275-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001MO-US00667.
XX
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483446/52.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brain -
XX
XX Example 4; SEQ ID NO: 32502; 650bp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human

CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention.
XX
SQ Sequence 50 AA;
XX
Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 955 LPADSCAIMEGED 968
DB 19 LPADSCAIMEGED 32
XX
RESULT 26
AAM73033
ID AAM73033 standard; Protein; 50 AA.
XX
XX AAM73033;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 33339.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma.
XX
XX Homo sapiens.
XX
XX MO200157276-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001MO-US00668.
XX
XX 04-FEB-2000; 2000US-0180312.
XX 26-MAY-2000; 2000US-0207456.
XX 30-JUN-2000; 2000US-0608408.
XX 03-AUG-2000; 2000US-0632366.
XX 21-SEP-2000; 2000US-0234687.
XX 27-SEP-2000; 2000US-0236359.
XX 04-OCT-2000; 2000GB-0024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488900/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for
XX analyzing gene expression in human bone marrow -
XX
XX Example 4; SEQ ID NO: 33339; 658bp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is a
XX protein encoded by one of the probes of the invention.
XX
SQ Sequence 50 AA;
XX
Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 955 LPADSCAIMEGED 968
DB 19 LPADSCAIMEGED 32


```

RESULT 27
AAM19811
ID AAM19811 standard; Protein; 50 AA.
XX
AC AAM19811;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #6245 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00670.
XX
PR 04-FEB-2000; 2000US-0180312.
XX
PR 26-MAY-2000; 2000US-0207456.
XX
PR 30-JUN-2000; 2000US-0608408.
XX
PR 03-AUG-2000; 2000US-0632366.
XX
PR 21-SEP-2000; 2000US-0234687.
XX
PR 27-SEP-2000; 2000US-0236359.
XX
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
XX
PT analyzing gene expression in human cervical epithelial cells -
XX
PS Claim 27; SEQ ID No 24637; 487bp; English.
XX
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AA128459). The present sequence is a peptide encoded
CC by one such probe. The SNPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 50 AA:
XX
Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 955 LPAADSCAIMEGSD 968
DB 19 LPAADSCAIMEGSD 32
XX
RESULT 28
AAM33257
ID AAM33257 standard; Protein; 50 AA.
XX
AC AAM33257;
XX
DT 17-OCT-2001 (first entry)
XX

```

```

DE Peptide #7294 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00663.
XX
PR 04-FEB-2000; 2000US-0180312.
XX
PR 26-MAY-2000; 2000US-0207456.
XX
PR 30-JUN-2000; 2000US-0608408.
XX
PR 03-AUG-2000; 2000US-0632366.
XX
PR 21-SEP-2000; 2000US-0234687.
XX
PR 27-SEP-2000; 2000US-0236359.
XX
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
XX
PT analyzing gene expression in human placenta -
XX
PS Claim 27; SEQ ID No 33526; 654bp; English.
XX
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI1315-AA157546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders.
XX
SQ Sequence 50 AA:
XX
Query Match 1.4%; Score 14; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 2.6e-06;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 955 LPAADSCAIMEGSD 968
DB 19 LPAADSCAIMEGSD 32
XX
RESULT 29
ABG42877
ID ABG42877 standard; Peptide; 50 AA.
XX
AC ABG42877;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 32542.
XX
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karsenger syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesia; pulmonary hypertension;
KW hyaline membrane disease.
XX
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX

```


PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 13-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 20-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.

PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251858.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 XX
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 XX
 DR WPI; 2001-488782/53.
 XX N-PSDB; AAB34165.
 XX
 XX New polynucleotides and polypeptides for diagnosing, treating,
 PT preventing or prognosing e.g. diseases or disorders of the nervous,
 PT musculoskeletal, excretory, gastrointestinal, reproductive, and
 PT respiratory systems -
 XX
 PS Claim 11; SEQ ID NO 1589; 642pp; English.
 XX
 XX The invention relates to novel nucleic acids encoding novel human foetal
 CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
 CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
 CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
 CC are also used in diagnosing a pathological condition or susceptibility
 CC to a pathological condition. The antibodies to the antigens can also
 CC be used in alleviating symptoms associated with the disorders and in
 CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
 CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
 CC include autoimmune diseases e.g. rheumatoid arthritis,
 CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
 CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
 CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
 CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
 CC and ocular disorders e.g. corneal infection. The polypeptides can also
 CC be used to aid wound healing and epithelial cell proliferation, to
 CC prevent skin aging due to sunburn, to maintain organs before
 CC transplantation, for supporting cell culture of primary tissues, to
 CC regenerate tissues and in chemotaxis. The polypeptides can also be used
 CC as a food additive or preservative to increase or decrease storage
 CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
 CC minerals, cofactors and other nutritional components. Numerous
 CC examples of diseases and disorders treated by the nucleic acids and
 CC proteins are given in the specification. The present sequence

Query Match 1.4%; Score 14; DB 22; Length 71;
 Best Local Similarity 100.0%; Pred. No. 3.6e-06;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 955 LPAADSCAIMEGD 968
 |||||
 Db 16 LPAADSCAIMEGD 29

RESULT 31
 AAB70285
 ID AAB70285 standard; peptide; 78 AA.
 XX

```

AC AAB70285;
XX
XX 10-MAY-2001 (first entry)
XX
XX Peptide #29.
XX
XX TR16 receptor; tumour necrosis factor receptor superfamily;
XX apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
XX Unidentified.
XX
XX WO200112671-A1.
XX
XX 22-FEB-2001.
XX
XX 10-AUG-2000; 2000WO-US21885.
XX
XX 12-AUG-1999; 99US-0148348.
XX 13-AUG-1999; 99US-0148683.
XX 13-AUG-1999; 99US-0148870.
XX 16-AUG-1999; 99US-0148758.
XX 17-AUG-1999; 99US-0149181.
XX 18-AUG-1999; 99US-0149453.
XX 19-AUG-1999; 99US-0149498.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Young PE, Baker KP;
XX
XX WPI; 2001-138754/14.
XX
XX New nucleic acid molecule encoding a TR16 tumor necrosis factor
XX receptor polypeptide, useful for the diagnosis and treatment of cancer,
XX autoimmune disorders and cardiovascular diseases -
XX
XX Disclosure; Page 81; 286pp; English.
XX
XX The present invention relates to a TR16 receptor (tumour necrosis
XX factor receptor superfamily). The invention is useful treating
XX diseases and disorders associated with the inhibited or increased
XX apoptosis, in particular inflammatory diseases, cancers, immune and
XX neurodegenerative disorders may be treated.
XX
XX Sequence 78 AA;
XX
XX Query Match 1.4%; Score 14; DB 22; Length 78;
XX Best Local Similarity 100.0%; Pred. No. 3.9e-06;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 933 KNOXLEYKYSKLVLM 946
XX 1 KNOXLEYKYSKLVLM 14
XX
XX Db
XX
XX RESULT 32
XX AAB27114
XX ID AAB27114 standard; Protein; 10 AA.
XX
XX AC AAB27114;
XX
XX 12-FEB-2001 (first entry)
XX
XX Human CASB619 protein epitope SEQ ID NO: 40.
XX
XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
XX
XX Homo sapiens.
XX
XX WO200058460-A2.
XX
XX 05-OCT-2000.
XX

```

```

PF 20-MAR-2000; 2000WO-EP02478.
XX
XX 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
XX WPI; 2000-664923/64.
XX
XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases -
XX
XX Example 7; Page 62; 68pp; English.
XX
XX The present sequence comprises an epitope derived from the human CASB619
XX protein sequence. This protein is thought to be specifically or
XX over-expressed in tumour cells, and so can be used as a target for
XX antigen-specific immune responses which can cause destruction of the
XX tumour cell. In addition, the protein and gene can be used in cancer
XX diagnosis, in the treatment of autoimmune diseases and in vaccines
XX against cancer and autoimmune disease. The present sequence can be used
XX as an immunogen.
XX
XX Sequence 10 AA;
XX
XX Query Match 1.0%; Score 10; DB 21; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 0.01;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 866 AIVSSCVAGI 875
XX 1 AIVSSCVAGI 10
XX
XX Db
XX
XX RESULT 33
XX AAB27115
XX ID AAB27115 standard; Protein; 10 AA.
XX
XX AC AAB27115;
XX
XX 12-FEB-2001 (first entry)
XX
XX Human CASB619 protein epitope SEQ ID NO: 41.
XX
XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
XX
XX Homo sapiens.
XX
XX WO200058460-A2.
XX
XX 05-OCT-2000.
XX
XX 20-MAR-2000; 2000WO-EP02478.
XX
XX 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
XX WPI; 2000-664923/64.
XX
XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases -
XX
XX Example 7; Page 62; 68pp; English.
XX

```

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX
 SQ Sequence 10 AA;

Query Match

Best Local Similarity 1.0%; Score 10; DB 21; Length 10;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 852 SAACPLCSV 861
 DB 1 SAACPLCSV 10

RESULT 34

ID AAB27116 standard; Protein; 10 AA.

AC AAB27116;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 42.

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Caesart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 62; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX
 SQ Sequence 10 AA;

Query Match

Best Local Similarity 1.0%; Score 10; DB 21; Length 10;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 786 HLESIGIPDV 795
 |||||

DB 1 HLESIGIPDV 10

RESULT 35

ID AAB27117 standard; Protein; 10 AA.

AC AAB27117;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 43.

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Caesart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 62; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX
 SQ Sequence 10 AA;

Query Match

Best Local Similarity 1.0%; Score 10; DB 21; Length 10;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 571 KIYSINVTNV 580
 |||||

DB 1 KIYSINVTNV 10

RESULT 36

ID AAB27118 standard; Protein; 10 AA.

AC AAB27118;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 44.

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 epitope.

OS Homo sapiens.

```

XX PN WO200058460-A2.
XX PS 05-OCT-2000.
XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX DR WPI; 2000-664923/64.
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX PS Example 7; Page 62; 68pp; English.
XX CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred.No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 761 SLADRLIGVT 770
DB 1 SLADRLIGVT 10

RESULT 37
AAB27119
ID AAB27119 standard; Protein; 10 AA.
XX AC AAB27119;
XX DT 12-FEB-2001 (first entry)
XX DE Human CASB619 protein epitope SEQ ID NO: 45.
XX KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX KM epitope.
XX OS Homo sapiens.
XX PN WO200058460-A2.
XX PD 05-OCT-2000.
XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX DR WPI; 2000-664923/64.
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for

```

```

PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX PS Example 7; Page 62; 68pp; English.
XX CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred.No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 ILKAHQPYGV 635
DB 1 ILKAHQPYGV 10

RESULT 38
AAB27120
ID AAB27120 standard; Protein; 10 AA.
XX AC AAB27120;
XX DT 12-FEB-2001 (first entry)
XX DE Human CASB619 protein epitope SEQ ID NO: 46.
XX KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX KM epitope.
XX OS Homo sapiens.
XX PN WO200058460-A2.
XX PD 05-OCT-2000.
XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX DR WPI; 2000-664923/64.
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX PS Example 7; Page 63; 68pp; English.
XX CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
XX SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;

```


Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 485 VMADTENKEV 494
|||||

DB 1 VMADTENKEV 10

RESULT 39

AAB27121
ID AAB27121 standard; Protein; 10 AA.

AC AAB27121;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 47.

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Basols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
propylactic and therapeutic treatment of, cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 63; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
protein sequence. This protein is thought to be specifically or

CC over-expressed in tumour cells, and so can be used as a target for
antigen-specific immune responses which can cause destruction of the

CC tumour cell. In addition, the protein and gene can be used in cancer
diagnosis, in the treatment of autoimmune diseases and in vaccines

CC against cancer and autoimmune disease. The present sequence can be used
as an immunogen.

CC Sequence 10 AA;

QY Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 LLMAGTAFQV 38
|||||

DB 1 LLMAGTAFQV 10

RESULT 40

AAB27122
ID AAB27122 standard; Protein; 10 AA.

AC AAB27122;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 48.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Basols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
propylactic and therapeutic treatment of, cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 63; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
protein sequence. This protein is thought to be specifically or

CC over-expressed in tumour cells, and so can be used as a target for
antigen-specific immune responses which can cause destruction of the

CC tumour cell. In addition, the protein and gene can be used in cancer
diagnosis, in the treatment of autoimmune diseases and in vaccines

CC against cancer and autoimmune disease. The present sequence can be used
as an immunogen.

CC Sequence 10 AA;

QY Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 GTCTAIIITV 925
|||||

DB 1 GTCTAIIITV 10

RESULT 41

AAB27123
ID AAB27123 standard; Protein; 10 AA.

AC AAB27123;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 49.

KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX WPI; 2000-664923/64.
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 63; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 SQ Sequence 10 AA;
 XX
 Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 778 ITSPALFHL 787
 DB 1 ITSPALFHL 10
 XX
 RESULT 42
 AAB27124
 ID AAB27124 standard; Protein; 10 AA.
 XX
 XX AAB27124;
 AC
 XX 12-FEB-2001 (first entry)
 DT
 XX Human CASB619 protein epitope SEQ ID NO: 50.
 DE
 XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 KW
 XX Homo sapiens.
 OS
 XX WO200058460-A2.
 PN
 XX 05-OCT-2000.
 PD
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 XX 26-MAR-1999; 99GB-0007113.
 PR
 XX 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX
 XX WPI; 2000-664923/64.
 DR
 XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 63; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used

CC as an immunogen.
 XX
 SQ Sequence 10 AA;
 XX
 Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 766 LIGVTDMTL 775
 DB 1 LIGVTDMTL 10
 XX
 RESULT 43
 AAB27125
 ID AAB27125 standard; Protein; 10 AA.
 XX
 XX AAB27125;
 AC
 XX 12-FEB-2001 (first entry)
 DT
 XX Human CASB619 protein epitope SEQ ID NO: 51.
 DE
 XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 KW
 XX Homo sapiens.
 OS
 XX WO200058460-A2.
 PN
 XX 05-OCT-2000.
 PD
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 XX 26-MAR-1999; 99GB-0007113.
 PR
 XX 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX
 XX WPI; 2000-664923/64.
 DR
 XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 63; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 SQ Sequence 10 AA;
 XX
 Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 428 TLPTNMTTV 437
 DB 1 TLPTNMTTV 10
 XX
 RESULT 44
 AAB27126
 ID AAB27126 standard; Protein; 10 AA.
 XX

```

AC AAB27126;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 52.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Basols YC;
XX WPI; 2000-664923/64.
XX
DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 63; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
SQ
Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 350 LMYKWKAKPKI 359
DB 1 LMYKWKAKPKI 10

RESULT 45
AAB27128
ID AAB27128 standard; Protein; 10 AA.
XX
AC AAB27128;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 54.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX

```

```

PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Basols YC;
XX WPI; 2000-664923/64.
XX
DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 64; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC over-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.
SQ
Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 692 GLKYEHHFTL 701
DB 1 GLKYEHHFTL 10

RESULT 46
AAB27129
ID AAB27129 standard; Protein; 10 AA.
XX
AC AAB27129;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein epitope SEQ ID NO: 55.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Basols YC;
XX WPI; 2000-664923/64.
XX
DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Example 7; Page 64; 68pp; English.
XX
CC The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or

```

CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 644 GTKNKXIHSL 653
 DB 1 GTKNKXIHSL 10

RESULT 47

AA27130
 ID AAB27130 standard; Protein; 10 AA.

XX AAB27130;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 56.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;

KM epitope.

OS Homo sapiens.

XX WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Caesart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for

PT prophylactic and therapeutic treatment of, cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -

XX Example 7; Page 64; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 SDNDFMILT 474
 DB 1 SDNDFMILT 10

RESULT 48

AA27131
 ID AAB27131 standard; Protein; 10 AA.

XX AAB27131;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 57.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;

KM epitope.

OS Homo sapiens.

XX WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Caesart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -

XX Example 7; Page 64; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 260 LVNRNIAITGV 269
 DB 1 LVNRNIAITGV 10

RESULT 49

AA27132
 ID AAB27132 standard; Protein; 10 AA.

XX AAB27132;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 58.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;

KM epitope.

OS Homo sapiens.

XX WO200058460-A2.

```

XX 05-OCT-2000.
XX
XX 20-MAR-2000; 2000WO-EP02478.
XX
XX 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Casasart J, Coche T, Vinals De Bassols YC;
XX
XX WPI; 2000-664923/64.
XX
XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases
XX
XX Example 7; Page 64; 68pp; English.
XX
XX The present sequence comprises an epitope derived from the human CASB619
XX protein sequence. This protein is thought to be specifically or
XX over-expressed in tumour cells, and so can be used as a target for
XX antigen-specific immune responses which can cause destruction of the
XX tumour cell. In addition, the protein and gene can be used in cancer
XX diagnosis, in the treatment of autoimmune diseases and in vaccines
XX against cancer and autoimmune disease. The present sequence can be used
XX as an immunogen.
XX
XX Sequence 10 AA;
XX
XX Query Match 1.0%; Score 10; DB 21; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 0.01;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 77 GLCTSLPDV 86
XX |||||
XX 1 GLCTSLPDV 10
XX
XX Db
XX
XX RESULT 50
XX AAB27133
XX ID AAB27133 standard; Protein; 10 AA.
XX
XX AAB27133;
XX
XX 12-FEB-2001 (first entry)
XX
XX Human CASB619 protein epitope SEQ ID NO: 59.
XX
XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
XX
XX Homo sapiens.
XX
XX WO200058460-A2.
XX
XX 05-OCT-2000.
XX
XX 20-MAR-2000; 2000WO-EP02478.
XX
XX 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Casasart J, Coche T, Vinals De Bassols YC;
XX
XX WPI; 2000-664923/64.
XX
XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases

```

```

XX Example 7; Page 64; 68pp; English.
XX
XX The present sequence comprises an epitope derived from the human CASB619
XX protein sequence. This protein is thought to be specifically or
XX over-expressed in tumour cells, and so can be used as a target for
XX antigen-specific immune responses which can cause destruction of the
XX tumour cell. In addition, the protein and gene can be used in cancer
XX diagnosis, in the treatment of autoimmune diseases and in vaccines
XX against cancer and autoimmune disease. The present sequence can be used
XX as an immunogen.
XX
XX Sequence 10 AA;
XX
XX Query Match 1.0%; Score 10; DB 21; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 0.01;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 949 TLKDCDLPAA 958
XX |||||
XX 1 TLKDCDLPAA 10
XX
XX Db
XX
XX RESULT 51
XX AAB27134
XX ID AAB27134 standard; Protein; 10 AA.
XX
XX AAB27134;
XX
XX 12-FEB-2001 (first entry)
XX
XX Human CASB619 protein epitope SEQ ID NO: 60.
XX
XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX epitope.
XX
XX Homo sapiens.
XX
XX WO200058460-A2.
XX
XX 05-OCT-2000.
XX
XX 20-MAR-2000; 2000WO-EP02478.
XX
XX 26-MAR-1999; 99GB-0007113.
XX 25-SEP-1999; 99GB-0022858.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Casasart J, Coche T, Vinals De Bassols YC;
XX
XX WPI; 2000-664923/64.
XX
XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX prophylactic and therapeutic treatment of, cancers, particularly
XX ovarian and colon carcinoma, and autoimmune diseases
XX
XX Example 7; Page 65; 68pp; English.
XX
XX The present sequence comprises an epitope derived from the human CASB619
XX protein sequence. This protein is thought to be specifically or
XX over-expressed in tumour cells, and so can be used as a target for
XX antigen-specific immune responses which can cause destruction of the
XX tumour cell. In addition, the protein and gene can be used in cancer
XX diagnosis, in the treatment of autoimmune diseases and in vaccines
XX against cancer and autoimmune disease. The present sequence can be used
XX as an immunogen.
XX
XX Sequence 10 AA;
XX
XX Query Match 1.0%; Score 10; DB 21; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 0.01;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 795 VIFFYRNDV 804
 |||||
 DB 1 VIFFYRNDV 10

RESULT 52

AAB27135
 ID AAB27135 standard; Protein; 10 AA.

XX AAB27135;
 AC

XX 12-FEB-2001 (first entry)
 DT

XX Human CASB619 protein epitope SEQ ID NO: 61.
 DE

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 epitope.

XX Homo sapiens.
 OS

XX WO200058460-A2.
 PN

XX 05-OCT-2000.
 PD

XX 20-MAR-2000; 2000WO-EP02478.
 PF

XX 26-MAR-1999; 99GB-0007113.
 PR

XX 25-SEP-1999; 99GB-0022858.
 PR

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA

XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 PI

XX WPI; 2000-664923/64.
 DR

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly

XX ovarian and colon carcinoma, and autoimmune diseases -
 PT

XX Example 7; Page 65; 68pp; English.
 PS

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 10 AA;
 SQ

Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 733 SITAYVCOAV 742
 |||||

DB 1 SITAYVCOAV 10

RESULT 53

AAB27136
 ID AAB27136 standard; Protein; 10 AA.

XX AAB27136;
 AC

XX 12-FEB-2001 (first entry)
 DT

XX Human CASB619 protein epitope SEQ ID NO: 62.
 DE

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM

KM epitope.

XX Homo sapiens.
 OS

XX WO200058460-A2.
 PN

XX 05-OCT-2000.
 PD

XX 20-MAR-2000; 2000WO-EP02478.
 PF

XX 26-MAR-1999; 99GB-0007113.
 PR

XX 25-SEP-1999; 99GB-0022858.
 PR

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA

XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 PI

XX WPI; 2000-664923/64.
 DR

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly

XX ovarian and colon carcinoma, and autoimmune diseases -
 PT

XX Example 7; Page 65; 68pp; English.
 PS

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 10 AA;
 SQ

Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 712 SVCTDNTDL 721
 |||||

DB 1 SVCTDNTDL 10

RESULT 54

AAB27137
 ID AAB27137 standard; Protein; 10 AA.

XX AAB27137;
 AC

XX 12-FEB-2001 (first entry)
 DT

XX Human CASB619 protein epitope SEQ ID NO: 63.
 DE

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.

XX Homo sapiens.
 OS

XX WO200058460-A2.
 PN

XX 05-OCT-2000.
 PD

XX 20-MAR-2000; 2000WO-EP02478.
 PF

XX 26-MAR-1999; 99GB-0007113.
 PR

XX 25-SEP-1999; 99GB-0022858.
 PR

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA

XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 PI

DR WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX
XX Example 7; Page 65; 68pp; English.

XX The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC antigen-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.

XX Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 702 SLGNGQGRKM 711

Db 1 SLGNGQGRKM 10

RESULT 55

AAAB27138
ID AAB27138 standard; Protein; 10 AA.

XX AAB27138;

DT 12-FEB-2001 (first entry)

XX Human CASB619 protein epitope SEQ ID NO: 64.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KM epitope.

XX Homo sapiens.

XX WO200058460-A2.

XX 05-OCT-2000.

XX 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

XX 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX
XX Example 7; Page 65; 68pp; English.

XX The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC antigen-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.

SQ Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 432 NMETTVLSGI 441

Db 1 NMETTVLSGI 10

RESULT 56

AAAB27139
ID AAB27139 standard; Protein; 10 AA.

XX AAB27139;

DT 12-FEB-2001 (first entry)

XX Human CASB619 protein epitope SEQ ID NO: 65.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KM epitope.

XX Homo sapiens.

XX WO200058460-A2.

XX 05-OCT-2000.

XX 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

XX 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases
XX
XX Example 7; Page 65; 68pp; English.

XX The present sequence comprises an epitope derived from the human CASB619
CC protein sequence. This protein is thought to be specifically or
CC antigen-expressed in tumour cells, and so can be used as a target for
CC antigen-specific immune responses which can cause destruction of the
CC tumour cell. In addition, the protein and gene can be used in cancer
CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC against cancer and autoimmune disease. The present sequence can be used
CC as an immunogen.

XX Sequence 10 AA;

Query Match 1.0%; Score 10; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 NIAITGVAVT 272

Db 1 NIAITGVAVT 10

RESULT 57

AAAB27140
ID AAB27140 standard; Protein; 10 AA.

XX AAB27140;

DT 12-FEB-2001 (first entry)
 XX Human CASB619 protein epitope SEQ ID NO: 66.
 DE Human, CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX epitope.
 KM Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX WPI, 2000-664923/64.
 DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 65; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 10 AA;
 Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01; Mismatches 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 121 GIRFDEWDEL 130
 DB 1 GIRFDEWDEL 10
 RESULT 58
 AAB27141
 ID AAB27141 standard; Protein; 10 AA.
 AC AAB27141;
 DT 12-FEB-2001 (first entry)
 DE Human CASB619 protein epitope SEQ ID NO: 67.
 XX Human, CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX WPI, 2000-664923/64.
 DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 66; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 10 AA;
 Query Match 1.0%; Score 10; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.01; Mismatches 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 846 FHFLMESAAA 855
 DB 1 FHFLMESAAA 10
 RESULT 59
 AAB26181
 ID AAB26181 standard; Protein; 9 AA.
 AC AAB26181;
 DT 12-FEB-2001 (first entry)
 DE Human CASB619 protein epitope SEQ ID NO: 4.
 XX Human, CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX WPI, 2000-664923/64.
 DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 57; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the

CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 RLRRLILMA 32
 |||||
 DB 1 RLRRLILMA 9

RESULT 60

AAB26182
 ID AAB26182 standard; Protein; 9 AA.

AC AAB26182;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 5.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 57; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 761 SLADRLIGV 769
 |||||
 DB 1 SLADRLIGV 9

RESULT 61

AAB26183
 ID AAB26183 standard; Protein; 9 AA.

AC AAB26183;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 7.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 57; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 SLPRQRYTI 901
 |||||
 DB 1 SLPRQRYTI 9

RESULT 62

AAB26184
 ID AAB26184 standard; Protein; 9 AA.

AC AAB26184;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 8.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

```

XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX XX
XX PA (SMIK ) SMITHKLIN BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX XX WPI; 2000-664923/64.
XX DR
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX PT prophylactic and therapeutic treatment of, cancers, particularly
XX PT ovarian and colon carcinoma, and autoimmune diseases -
XX PS Example 7; Page 57; 68pp; English.

CC CC The present sequence comprises an epitope derived from the human CASB619
CC CC protein sequence. This protein is thought to be specifically or
CC CC over-expressed in tumour cells, and so can be used as a target for
CC CC antigen-specific immune responses which can cause destruction of the
CC CC tumour cell. In addition, the protein and gene can be used in cancer
CC CC diagnosis, in the treatment of autoimmune diseases and in vaccines
CC CC against cancer and autoimmune disease. The present sequence can be used
CC CC as an immunogen.
XX XX
XX SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 886 KLCGGGISTL 894
DB 1 KLCGGGISTL 9

RESULT 63
AAB26185
ID AAB26185 standard; Protein; 9 AA.
XX AC AAB26185;
XX DT 12-FEB-2001 (first entry)
XX DE Human CASB619 protein epitope SEQ ID NO: 9.
XX KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX KM epitope.
XX OS Homo sapiens.
XX OS WO200058460-A2.
XX PN 05-OCT-2000.
XX PD
XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX XX
XX PA (SMIK ) SMITHKLIN BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX XX WPI; 2000-664923/64.
XX DR
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX PT prophylactic and therapeutic treatment of, cancers, particularly
XX PT ovarian and colon carcinoma, and autoimmune diseases -
XX PS Example 7; Page 57; 68pp; English.

```

```

XX CC The present sequence comprises an epitope derived from the human CASB619
XX CC protein sequence. This protein is thought to be specifically or
XX CC over-expressed in tumour cells, and so can be used as a target for
XX CC antigen-specific immune responses which can cause destruction of the
XX CC tumour cell. In addition, the protein and gene can be used in cancer
XX CC diagnosis, in the treatment of autoimmune diseases and in vaccines
XX CC against cancer and autoimmune disease. The present sequence can be used
XX CC as an immunogen.
XX XX
XX SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 AAACPICSV 861
DB 1 AAACPICSV 9

RESULT 64
AAB26186
ID AAB26186 standard; Protein; 9 AA.
XX AC AAB26186;
XX DT 12-FEB-2001 (first entry)
XX DE Human CASB619 protein epitope SEQ ID NO: 10.
XX KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
XX KM epitope.
XX OS Homo sapiens.
XX OS WO200058460-A2.
XX PN 05-OCT-2000.
XX PD
XX PF 20-MAR-2000; 2000WO-EP02478.
XX PR 26-MAR-1999; 99GB-0007113.
XX PR 25-SEP-1999; 99GB-0022858.
XX XX
XX PA (SMIK ) SMITHKLIN BEECHAM BIOLOGICALS.
XX PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX XX WPI; 2000-664923/64.
XX DR
XX PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
XX PT prophylactic and therapeutic treatment of, cancers, particularly
XX PT ovarian and colon carcinoma, and autoimmune diseases -
XX PS Example 7; Page 57; 68pp; English.
XX CC The present sequence comprises an epitope derived from the human CASB619
XX CC protein sequence. This protein is thought to be specifically or
XX CC over-expressed in tumour cells, and so can be used as a target for
XX CC antigen-specific immune responses which can cause destruction of the
XX CC tumour cell. In addition, the protein and gene can be used in cancer
XX CC diagnosis, in the treatment of autoimmune diseases and in vaccines
XX CC against cancer and autoimmune disease. The present sequence can be used
XX CC as an immunogen.
XX XX
XX SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 SALANTVTL 682

```

Db 1 SALANTVTL 9

RESULT 65
AAB26187 standard; Protein; 9 AA.

AC AAB26187;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 11.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
prophylactic and therapeutic treatment of, cancers, particularly
ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 58; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
protein sequence. This protein is thought to be specifically or
over-expressed in tumour cells, and so can be used as a target for
antigen-specific immune responses which can cause destruction of the
tumour cell. In addition, the protein and gene can be used in cancer
diagnosis, in the treatment of autoimmune diseases and in vaccines
against cancer and autoimmune disease. The present sequence can be used
as an immunogen.

CC Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 FVFEETLCV 507
Db 1 FVFEETLCV 9

RESULT 66
AAB26188 standard; Protein; 9 AA.

AC AAB26188;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 12.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
prophylactic and therapeutic treatment of, cancers, particularly
ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 58; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
protein sequence. This protein is thought to be specifically or
over-expressed in tumour cells, and so can be used as a target for
antigen-specific immune responses which can cause destruction of the
tumour cell. In addition, the protein and gene can be used in cancer
diagnosis, in the treatment of autoimmune diseases and in vaccines
against cancer and autoimmune disease. The present sequence can be used
as an immunogen.

CC Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 129 ELPHGFASL 137
Db 1 ELPHGFASL 9

RESULT 67
AAB26190 standard; Protein; 9 AA.

AC AAB26190;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 14.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 58; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 SQ Sequence 9 AA;
 XX
 XX
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 936 KLEXYKSKL 944
 DB 1 KLEXYKSKL 9
 RESULT 68
 AAB26191
 ID AAB26191 standard; Protein; 9 AA.
 XX
 AC AAB26191;
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein epitope SEQ ID NO: 15.
 XX
 KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX
 OS Homo sapiens.
 XX
 PN WO200058460-A2.
 XX
 PD 05-OCT-2000.
 PS
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 58; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 SQ Sequence 9 AA;
 XX
 XX
 Sequence 9 AA;
 DT 12-FEB-2001 (first entry)

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 903 KTIQFWLKV 911
 DB 1 KTIQFWLKV 9
 RESULT 69
 AAB26192
 ID AAB26192 standard; Protein; 9 AA.
 XX
 AC AAB26192;
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein epitope SEQ ID NO: 16.
 XX
 KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX
 OS Homo sapiens.
 XX
 PN WO200058460-A2.
 XX
 PD 05-OCT-2000.
 PS
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 58; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 SQ Sequence 9 AA;
 XX
 XX
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 860 SVADYHAIV 868
 DB 1 SVADYHAIV 9
 RESULT 70
 AAB26193
 ID AAB26193 standard; Protein; 9 AA.
 XX
 AC AAB26193;
 DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 17.
 XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.
 XX Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 XX WPI; 2000-664923/64.
 XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 58; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX Sequence 9 AA;
 SQ
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 830 LLLPCTCSD 838
 DB 1 LLLPCTCSD 9
 RESULT 71
 AAB26194
 ID AAB26194 standard; Protein; 9 AA.
 XX AAB26194;
 AC 12-FEB-2001 (first entry)
 XX Human CASB619 protein epitope SEQ ID NO: 18.
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.
 XX Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 XX WPI; 2000-664923/64.
 XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 59; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX Sequence 9 AA;
 SQ
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 675 ALANTVTLA 683
 DB 1 ALANTVTLA 9
 RESULT 72
 AAB26195
 ID AAB26195 standard; Protein; 9 AA.
 XX AAB26195;
 AC 12-FEB-2001 (first entry)
 XX Human CASB619 protein epitope SEQ ID NO: 19.
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.
 XX Homo sapiens.
 XX WO200058460-A2.
 XX 05-OCT-2000.
 XX 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX Bruck CEM, Cascart J, Coche T, Vinals De Bassols YC;
 XX WPI; 2000-664923/64.
 XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 XX Example 7; Page 59; 68pp; English.
 XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines

CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX
 SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 503 TLCSVNCCL 511
 DB 1 TLCSVNCCL 9

RESULT 73
 AAB26196
 ID AAB26196 standard; Protein; 9 AA.
 XX

AC AAB26196;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 20.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 DR WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PI ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 59; 68pp; English.

XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 169 NTDECTATL 177

DB 1 NTDECTATL 9

RESULT 74
 AAB26197
 ID AAB26197 standard; Protein; 9 AA.

XX AAB26197;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 21.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 DR WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PI ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 59; 68pp; English.

XX The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

SQ Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 SLDDPVKGT 89

DB 1 SLDDPVKGT 9

RESULT 75
 AAB26199
 ID AAB26199 standard; Protein; 9 AA.

AC AAB26199;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 23.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PF 20-MAR-2000; 2000WO-EP02478.

RESULT 78
 AAB26202
 ID AAB26202 standard; Protein; 9 AA.
 AC AAB26202;
 XX
 DT 12-FEB-2001 (first entry)
 DE Human CASB619 protein epitope SEQ ID NO: 26.
 XX
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 OS epitope.
 XX Homo sapiens.
 OS
 PN WO200058460-A2.
 PD 05-OCT-2000..
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 DR WPI; 2000-664923/64.
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of cancers, particularly
 XX ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 60; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX
 SQ Sequence 9 AA;
 Query Match
 Best Local Similarity 0.9%; Score 9; DB 21; Length 9;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 259 VLVNRNIAIT 267
 DB 1 VLVNRNIAIT 9
 RESULT 79
 AAB27101
 ID AAB27101 standard; Protein; 9 AA.
 AC AAB27101;
 XX
 DT 12-FEB-2001 (first entry)
 DE Human CASB619 protein epitope SEQ ID NO: 27.
 XX
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 OS epitope.
 XX Homo sapiens.
 OS

PN. WO200058460-A2.
 XX
 PD 05-OCT-2000..
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 DR WPI; 2000-664923/64.
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of cancers, particularly
 XX ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 60; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX
 SQ Sequence 9 AA;
 Query Match
 Best Local Similarity 0.9%; Score 9; DB 21; Length 9;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 234 ELNRGNVVL 242
 DB 1 ELNRGNVVL 9
 RESULT 80
 AAB27102
 ID AAB27102 standard; Protein; 9 AA.
 AC AAB27102;
 XX
 DT 12-FEB-2001 (first entry)
 DE Human CASB619 protein epitope SEQ ID NO: 28.
 XX
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 OS epitope.
 XX Homo sapiens.
 OS
 PN WO200058460-A2.
 PD 05-OCT-2000..
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 XX 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 DR WPI; 2000-664923/64.
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of cancers, particularly

PT ovarian and colon carcinoma, and autoimmune diseases -
 XX
 PS Example 7; Page 60; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

CC Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0;

QY 175 ATLMTAVNL 183
 |||||
 1 ATLMTAVNL 9

RESULT 81

AAB27103
 ID AAB27103 standard; Protein; 9 AA.

AC AAB27103;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 29.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;

KW epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PP 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 60; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

CC Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 70 VAVPHTPGL 78
 |||||
 1 VAVPHTPGL 9

RESULT 82

AAB27104
 ID AAB27104 standard; Protein; 9 AA.

AC AAB27104;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 30.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;

KW epitope.

OS Homo sapiens.

PN WO200058460-A2.

PD 05-OCT-2000.

PP 20-MAR-2000; 2000WO-EP02478.

PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.

PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;

DR WPI; 2000-664923/64.

PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -

PS Example 7; Page 60; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

CC Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0;

QY 24 RWRLLTMA 32
 |||||
 1 RWRLLTMA 9

RESULT 83

AAB27105
 ID AAB27105 standard; Protein; 9 AA.

AC AAB27105;

DT 12-FEB-2001 (first entry)

DE Human CASB619 protein epitope SEQ ID NO: 31.

KM Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

XX Homo sapiens.

OS WO200058460-A2.

XX 05-OCT-2000.

XX 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

XX 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cassart J, Coche T, Vinals De Baesols YC;

XX WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 XX ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 60; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred No. 7.8e+05;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 914 SAGCTCTAIL 922

Db 1 SAGCTCTAIL 9

RESULT 84

XX AAB27106 standard; Protein; 9 AA.

XX AAB27106;

XX 12-FEB-2001 (first entry)

XX Human CASB619 protein epitope SEQ ID NO. 32.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

XX Homo sapiens.

XX WO200058460-A2.

XX 05-OCT-2000.

XX 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

XX 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cassart J, Coche T, Vinals De Baesols YC;

XX WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 XX ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 61; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX Sequence 9 AA;

Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 891 GISLPEQRY 899

Db 1 GISLPEQRY 9

RESULT 85

XX AAB27107 standard; Protein; 9 AA.

XX AAB27107;

XX 12-FEB-2001 (first entry)

XX Human CASB619 protein epitope SEQ ID NO. 33.

XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.

XX Homo sapiens.

XX WO200058460-A2.

XX 05-OCT-2000.

XX 20-MAR-2000; 2000WO-EP02478.

XX 26-MAR-1999; 99GB-0007113.

XX 25-SEP-1999; 99GB-0022858.

XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.

XX Bruck CEM, Cassart J, Coche T, Vinals De Baesols YC;

XX WPI; 2000-664923/64.

XX Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 XX ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7; Page 61; 68pp; English.

CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.

XX SQ Sequence .9 AA;
 XX Query Match 0.9%; Score 9; DB 21; Length 9;
 XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 824 KTVPGSLL 832
 DB 1 KTVPGSLL 9
 RESULT 86
 AAB27108
 ID AAB27108 standard; Protein; 9 AA.
 AC AAB27108;
 XX 12-FEB-2001 (first entry)
 DT Human CASB619 protein epitope SEQ ID NO: 34.
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX Homo sapiens.
 OS WO200058460-A2.
 PN 05-OCT-2000.
 PD 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 XX prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases
 PS Example 7; Page 61; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX SQ Sequence 9 AA;
 QY Query Match 0.9%; Score 9; DB 21; Length 9;
 XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 765 RLIGVTTDM 773
 DB 1 RLIGVTTDM 9
 RESULT 87
 AAB27109
 ID AAB27109 standard; Protein; 9 AA.
 AC AAB27109;

XX 12-FEB-2001 (first entry)
 DT Human CASB619 protein epitope SEQ ID NO: 35.
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX Homo sapiens.
 OS WO200058460-A2.
 PN 05-OCT-2000.
 PD 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 XX prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases
 PS Example 7; Page 61; 68pp; English.
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 XX SQ Sequence 9 AA;
 QY Query Match 0.9%; Score 9; DB 21; Length 9;
 XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 681 TLAGPSFT 689
 DB 1 TLAGPSFT 9
 RESULT 88
 AAB27110
 ID AAB27110 standard; Protein; 9 AA.
 AC AAB27110;
 XX 12-FEB-2001 (first entry)
 DT Human CASB619 protein epitope SEQ ID NO: 36.
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KM epitope.
 XX Homo sapiens.
 OS WO200058460-A2.
 PN 05-OCT-2000.
 PD 20-MAR-2000; 2000WO-EP02478.
 XX 26-MAR-1999; 99GB-0007113.
 PR 26-MAR-1999; 99GB-0007113.

PR 25-SEP-1999; 99GB-0022858.
 XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7, Page 61, 68pp; English.
 XX
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 9 AA;
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 539 YIIENNTT 547
 DB 1 YIIENNTT 9
 RESULT 89
 AAB27111
 ID AAB27111 standard; Protein; 9 AA.
 XX
 AC AAB27111;
 XX
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein epitope SEQ ID NO: 37.
 XX
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.
 OS Homo sapiens.
 OS
 XX
 PN WO200058460-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7, Page 61, 68pp; English.
 XX
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 9 AA;
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 38 VTGGTGPETL 46
 DB 1 VTGGTGPETL 9

CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 9 AA;
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 264 IATGVAVT 272
 DB 1 IATGVAVT 9

RESULT 90
 AAB27112
 ID AAB27112 standard; Protein; 9 AA.
 XX
 AC AAB27112;
 XX
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein epitope SEQ ID NO: 38.
 XX
 KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 KW epitope.
 OS Homo sapiens.
 OS
 XX
 PN WO200058460-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 20-MAR-2000; 2000WO-EP02478.
 XX
 PR 26-MAR-1999; 99GB-0007113.
 PR 25-SEP-1999; 99GB-0022858.
 XX
 PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA
 PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 PI WPI; 2000-664923/64.
 DR
 XX
 PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 PT prophylactic and therapeutic treatment of, cancers, particularly
 PT ovarian and colon carcinoma, and autoimmune diseases -
 PS Example 7, Page 61, 68pp; English.
 XX
 CC The present sequence comprises an epitope derived from the human CASB619
 CC protein sequence. This protein is thought to be specifically or
 CC over-expressed in tumour cells, and so can be used as a target for
 CC antigen-specific immune responses which can cause destruction of the
 CC tumour cell. In addition, the protein and gene can be used in cancer
 CC diagnosis, in the treatment of autoimmune diseases and in vaccines
 CC against cancer and autoimmune disease. The present sequence can be used
 CC as an immunogen.
 CC
 SQ Sequence 9 AA;
 Query Match 0.9%; Score 9; DB 21; Length 9;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 38 VTGGTGPETL 46
 DB 1 VTGGTGPETL 9

RESULT 91
 AAB27142
 ID AAB27142 standard; Protein; 9 AA.
 XX
 AC AAB27142;
 DT 12-FEB-2001 (first entry)
 XX
 DE Human CASB619 protein epitope SEQ ID NO: 68.
 XX
 DE Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
 XX
 DE epitope.
 XX
 DE Homo sapiens.
 XX
 DE WO200058460-A2.
 XX
 DE 05-OCT-2000.
 XX
 DE 20-MAR-2000; 2000MO-EP02478.
 XX
 DE 26-MAR-1999; 99GB-0007113.
 XX
 DE 25-SEP-1999; 99GB-0022858.
 XX
 DE (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 DE Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
 XX
 DE WPI; 2000-664923/64.
 XX
 DE Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
 XX
 DE prophylactic and therapeutic treatment of, cancers, particularly
 XX
 DE ovarian and colon carcinoma, and autoimmune diseases
 XX
 DE Example 7; Page 66; 68pp; English.
 XX
 DE The present sequence comprises an epitope derived from the human CASB619
 XX
 DE protein sequence. This protein is thought to be specifically or
 XX
 DE over-expressed in tumour cells, and so can be used as a target for
 XX
 DE antigen-specific immune responses which can cause destruction of the
 XX
 DE tumour cell. In addition, the protein and gene can be used in cancer
 XX
 DE diagnosis, in the treatment of autoimmune diseases and in vaccines
 XX
 DE against cancer and autoimmune disease. The present sequence can be used
 XX
 DE as an immunogen.
 XX
 DE Sequence 9 AA;
 XX
 DE Query Match 0.9%; Score 9; DB 21; Length 9;
 XX
 DE Best Local Similarity 100.0%; Pred. No. 7.8e+05; Indels 0;
 XX
 DE Matches 9; Conservative 0; Mismatches 0; Gaps 0;
 XX
 DE QY 848 FLMESAAAC 856
 XX
 DE 1 FLMESAAAC 9
 XX
 DE DB
 XX
 DE RESULT 92
 XX
 DE ABB38903
 XX
 DE ID ABB38903 standard; Peptide; 32 AA.
 XX
 DE AC ABB38903;
 XX
 DE DT 04-FEB-2002 (first entry)
 XX
 DE Peptide #6409 encoded by human foetal liver single exon probe.
 XX
 DE Human; foetal liver; gene expression; single exon nucleic acid probe.
 XX
 DE Homo sapiens.
 XX
 DE WO200157277-A2.
 XX
 DE 09-AUG-2001.

XX
 XX 30-JAN-2001; 2001WO-US00669.
 XX
 XX 04-FEB-2000; 2000US-0180312.
 XX
 XX 26-MAY-2000; 2000US-0207456.
 XX
 XX 30-JUN-2000; 2000US-0608408.
 XX
 XX 03-AUG-2000; 2000US-0632366.
 XX
 XX 21-SEP-2000; 2000US-0234687.
 XX
 XX 27-SEP-2000; 2000US-0236359.
 XX
 XX 04-OCT-2000; 2000GB-0024263.
 XX
 XX (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 XX Penn SG, Hanzel DK, Chen W, Rank DR;
 XX
 XX WPI; 2001-483447/52.
 XX
 XX Human genome-derived single exon nucleic acid probes useful for
 XX
 XX analyzing gene expression in human fetal liver -
 XX
 XX Claim 27; SEQ ID NO 31538; 639pp + sequence listing; English.
 XX
 XX The invention relates to a single exon nucleic acid probe for
 XX
 XX measuring human gene expression in a sample derived from human foetal
 XX
 XX liver. The single exon nucleic acid probes may be used for predicting,
 XX
 XX measuring and displaying gene expression in samples derived from human
 XX
 XX foetal liver. The present sequence is a peptide encoded by a single exon
 XX
 XX nucleic acid probe of the invention.
 XX
 XX Note: The sequence data for this patent did not form part of the
 XX
 XX printed specification, but was obtained in electronic format directly
 XX
 XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 XX Sequence 32 AA;
 XX
 XX Query Match 0.9%; Score 9; DB 22; Length 32;
 XX
 XX Best Local Similarity 100.0%; Pred. No. 0.33; Indels 0; Gaps 0;
 XX
 XX Matches 9; Conservative 0; Mismatches 0;
 XX
 XX QY 964 MEGEDVEDD 972
 XX
 XX DB 1 MEGEDVEDD 9
 XX
 XX RESULT 93
 XX
 XX ABB23896
 XX
 XX ID ABB23896 standard; Protein; 32 AA.
 XX
 XX AC ABB23896;
 XX
 XX DT 23-JAN-2002 (first entry)
 XX
 XX Protein #5895 encoded by probe for measuring heart cell gene expression.
 XX
 XX Human; gene expression; heart; microarray; vascular system;
 XX
 XX cardiovascular disease; hypertension; cardiac arrhythmia;
 XX
 XX congenital heart disease.
 XX
 XX Homo sapiens.
 XX
 XX WO200157274-A2.
 XX
 XX 09-AUG-2001.
 XX
 XX 30-JAN-2001; 2001WO-US00666.
 XX
 XX 04-FEB-2000; 2000US-0180312.
 XX
 XX 26-MAY-2000; 2000US-0207456.
 XX
 XX 30-JUN-2000; 2000US-0608408.
 XX
 XX 03-AUG-2000; 2000US-0632366.
 XX
 XX 21-SEP-2000; 2000US-0234687.
 XX
 XX 27-SEP-2000; 2000US-0236359.
 XX
 XX 04-OCT-2000; 2000GB-0024263.
 XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-48899/53.

PT Single exon nucleic acid probes for analyzing gene expression in human

PT hearts

PS Claim 15; SEQ ID No 25666; 530pp; English.

CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA2155-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular diseases of the
CC hypertension, cardiac arrhythmias and congenital heart disease.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

SQ Sequence 32 AA;

Query Match

Best Local Similarity 0.9%; Score 9; DB 22; Length 32;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 964 MEGEDVEDD 972

DB 1 MEGEDVEDD 9

RESULT 94

AA59554

XX AAM59554 standard; Protein; 32 AA.

XX AAM59554;

XX 05-NOV-2001 (first entry)

XX Human brain expressed single exon probe encoded protein SEQ ID NO: 31659.

XX Human; brain expressed exon; gene expression analysis; probe;

XX microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;

XX epilepsy; cancer.

XX Homo sapiens.

XX WO200157275-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US00667.

XX 04-FEB-2000; 2000US-0180312.

XX 26-MAY-2000; 2000US-0207456.

XX 30-JUN-2000; 2000US-0608408.

XX 03-AUG-2000; 2000US-0632366.

XX 21-SEP-2000; 2000US-0234687.

XX 27-SEP-2000; 2000US-0236359.

XX 04-OCT-2000; 2000GB-0024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-483446/52.

XX Single exon nucleic acid probes for analyzing gene expression in human

XX brains

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX Example 4; SEQ ID NO: 31659; 650pp + Sequence Listing; English.

CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancer. The present sequence is a protein encoded by one of
CC the probes of the invention.

SQ Sequence 32 AA;

Query Match

Best Local Similarity 0.9%; Score 9; DB 22; Length 32;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 964 MEGEDVEDD 972

DB 1 MEGEDVEDD 9

RESULT 95

AA72123

XX AAM72123 standard; Protein; 32 AA.

XX AAM72123;

XX 06-NOV-2001 (first entry)

XX Human bone marrow expressed probe encoded protein SEQ ID NO: 32429.

XX Human; bone marrow expressed exon; gene expression analysis; probe;

XX microarray; cancer; leukemia; lymphoma; myeloma.

XX Homo sapiens.

XX WO200157276-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US00668.

XX 04-FEB-2000; 2000US-0180312.

XX 26-MAY-2000; 2000US-0207456.

XX 30-JUN-2000; 2000US-0608408.

XX 03-AUG-2000; 2000US-0632366.

XX 21-SEP-2000; 2000US-0234687.

XX 27-SEP-2000; 2000US-0236359.

XX 04-OCT-2000; 2000GB-0024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-48890/53.

XX Human genome-derived single exon nucleic acid probes useful for

XX analyzing gene expression in human bone marrow

XX Example 4; SEQ ID NO: 32429; 658pp + Sequence Listing; English.

XX The present invention provides a number of single exon nucleic acid

XX probes which are derived from genomic sequences expressed in the human

XX bone marrow. They can be used to measure gene expression in bone marrow

XX samples, which may enable the improved diagnosis and treatment of cancers

XX such as lymphoma, leukemia and myeloma. The present sequence is a

XX protein encoded by one of the probes of the invention.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 964 MEGEDVEDD 972

Db 1 MEGEDVEDD 9

RESULT 96

AAAM19447 standard; Protein; 32 AA.

AAAM19447;

12-OCT-2001 (first entry)

Peptide #5881 encoded by probe for measuring cervical gene expression.

Probe; human; microarray; gene expression; cervical epithelial cell;

cervical cancer.

Homo sapiens.

MO200157278-A2.

09-AUG-2001.

30-JAN-2001; 2001WO-US00670.

04-FEB-2000; 2000US-0180312.

26-MAY-2000; 2000US-0207456.

30-JUN-2000; 2000US-0608408.

03-AUG-2000; 2000US-0632366.

21-SEP-2000; 2000US-0234687.

27-SEP-2000; 2000US-0236359.

04-OCT-2000; 2000GB-0024263.

(MOLE-) MOLECULAR DYNAMICS INC.

Penn SG, Hanzel DK, Chen W, Rank DR;

WPI; 2001-488901/53.

Human genome-derived single exon nucleic acid probes useful for

analyzing gene expression in human cervical epithelial cells -

Claim 27; SEQ ID No 24273; 487bp; English.

The present invention relates to human single exon nucleic acid probes

(SENP; see A110068-A128459). The present sequence is a peptide encoded

by one such probe. The SENPs are derived from human HeLa cells. The SENPs

can be used to produce a single exon microarray, which can be used for

measuring human gene expression in a sample derived from human cervical

epithelial cells. By measuring gene expression, the probes are therefore

useful in grading and/or staging of diseases of the cervix, notably

cervical cancer.

Note: The sequence data for this patent did not form part of the printed

specification, but was obtained in electronic format directly from WIPO

at ftp.wipo.int/pub/published_pct_sequences.

XX AAAM32385;

AC 17-OCT-2001 (first entry)

Peptide #6422 encoded by probe for measuring placental gene expression.

Probe; microarray; human; placenta; antenatal diagnosis;

genetic disorder.

Homo sapiens.

MO200157272-A2.

09-AUG-2001.

30-JAN-2001; 2001WO-US00663.

04-FEB-2000; 2000US-0180312.

26-MAY-2000; 2000US-0207456.

30-JUN-2000; 2000US-0608408.

03-AUG-2000; 2000US-0632366.

21-SEP-2000; 2000US-0234687.

27-SEP-2000; 2000US-0236359.

04-OCT-2000; 2000GB-0024263.

(MOLE-) MOLECULAR DYNAMICS INC.

Penn SG, Hanzel DK, Chen W, Rank DR;

WPI; 2001-48897/53.

Human genome-derived single exon nucleic acid probes useful for

analyzing gene expression in human placenta -

Claim 27; SEQ ID No 32654; 654bp; English.

The present invention relates to single exon nucleic acid probes (SENP;

see A113315-A1157546). The present sequence is a peptide encoded by one

such probe. The probes are useful for producing a microarray for

predicting, measuring and displaying gene expression in samples derived

from human placenta. The probes are useful for antenatal diagnosis of

human genetic disorders.

Sequence 32 AA;

Query Match

Best Local Similarity 100.0%; Score 9; DB 22; Length 32;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 964 MEGEDVEDD 972

Db 1 MEGEDVEDD 9

RESULT 98

ABG41937 standard; Peptide; 32 AA.

ABG41937;

19-AUG-2002 (first entry)

Human peptide encoded by genome-derived single exon probe SEQ ID 31602.

Human; single exon probe; asthma; lung cancer; COPD; ILD;

chronic obstructive pulmonary disease; interstitial lung disease;

familial idiopathic pulmonary fibrosis; neurofibromatosis;

tuberosus sclerosis; Gaucher's disease; Niemann-Pick disease;

Hernandez-Pudlak syndrome; sarcoidosis; pulmonary haemostasis;

pulmonary histiocytosis; lymphangiomyomatosis; Karsenger syndrome;

pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;

primary ciliary dyskinesia; pulmonary hypertension;

KM hyaline membrane disease.
 XX Homo sapiens.
 XX WO200186003-A2.
 XX 15-NOV-2001.
 XX 30-JAN-2001; 2001WO-US00665.
 XX 04-FEB-2000; 2000US-180312P.
 XX 26-MAY-2000; 2000US-207456P.
 XX 30-JUN-2000; 2000US-0608408.
 XX 03-AUG-2000; 2000US-0632366.
 XX 21-SEP-2000; 2000US-234687P.
 XX 27-SEP-2000; 2000US-236359P.
 XX 04-OCT-2000; 2000GB-0024263.
 XX (MOLE-) MOLECULAR DYNAMICS INC.
 XX Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WPI; 2002-114183/15.
 XX Spatially-addressable set of single exon nucleic acid probes, used to
 XX measure gene expression in human lung samples -
 XX Claim 27, SEQ ID NO 31602; 634bp; English.
 XX The invention relates to a spatially-addressable set of single exon
 XX nucleic acid probes for measuring gene expression in a sample derived
 XX from human lung comprising single exon nucleic acid probes having one of
 XX 12614 nucleic acid sequences mentioned in the specification, or their
 XX complements or the 12387 open reading frames derived from the 12614
 XX probes. Also included are a microarray comprising the novel set of
 XX probes; the novel set of probes which hybridize at high stringency to a
 XX nucleic acid expressed in the human lung; measuring gene expression in a
 XX sample derived from human lung, comprising (a) contacting the array with
 XX a collection of detectably labeled nucleic acids derived from human lung
 XX mRNA, and (b) measuring the label detectably bound to each probe of
 XX the array; identifying exons in a eukaryotic genome, comprising
 XX (a) algorithmically predicting at least one exon from genomic sequences
 XX labeled nucleic acids from eukaryotic lung mRNA, to a single exon probe,
 XX having a fragment identical to the predicted exon, the probe is included
 XX in the above mentioned microarray; assigning exons to a single gene,
 XX comprising (a) identifying exons from genomic sequence by the method
 XX above and (b) measuring the expression of each of the exons in several
 XX tissues and/or cell types using hybridization to a single exon
 XX microarray having a probe with the exon, where a common pattern of
 XX expression of the exons in the tissues and/or cell types indicates that
 XX the exons should be assigned to a single gene; a peptide comprising one
 XX of 12011 sequences, mentioned in the specification, or encoded by the
 XX probes/open reading frames (ORF). The probes are used for gene
 XX expression analysis, and for identifying exons in a gene, particularly
 XX using human lung derived mRNA and for the study of lung diseases
 XX such as asthma, lung cancer, chronic obstructive pulmonary disease
 XX (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
 XX fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
 XX Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
 XX haemangioendothelioma, pulmonary histiocytosis, lymphangioleiomyomatosis,
 XX pulmonary alveolar proteinosis, Karsagen syndrome, fibrocystic
 XX pulmonary dysplasia, primary ciliary dyskinesia, pulmonary hypertension
 XX and hyaline membrane disease. The present sequence is a peptide/protein
 XX encoded by a single exon probe of the invention.
 XX Note: The sequence data for this patent did not form part
 XX of the printed specification, but was obtained in electronic
 XX format directly from WPIPO at
 XX ftp://wipo.int/pub/published_pct_sequences.
 XX Sequence 32 AA;

Best Local Similarity 100.0%; Pred. No. 0.33;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 964 MEGEDVEDD 972
 Db 1 MEGEDVEDD 9
 RESULT 99
 AAB57102
 ID AAB57102 standard; Protein; 519 AA.
 XX AC AAB57102;
 XX DT 13-MAR-2001 (first entry)
 XX DE Human prostate cancer antigen protein sequence SEQ ID NO:1680.
 XX KW Human; prostate cancer; prostate cancer antigen; detection; diagnosis;
 XX KW neuroprotective; cytoskeletal; cardioactive; immunomodulatory; muscular;
 XX KW vulnary; gastrointestinal; nephroprotective; antiinfective; gynaecological;
 XX KW gastrointestinal; gene therapy; neural; immune; reproductive; renal;
 XX KW wound; infectious disease.
 XX OS Homo sapiens.
 XX PN WO200055174-A1.
 XX PD 21-SEP-2000.
 XX PP 08-MAR-2000; 2000WO-US05988.
 XX PR 12-MAR-1999; 99US-0124270.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX RO (ROSE/) ROSEN C A.
 XX PI Rosen CA, Ruben SM;
 XX WPI; 2000-587513/55.
 XX DR N-PSDB; AAF16305.
 XX PT Prostate cancer associated gene sequences, referred to as prostate
 XX cancer antigens, useful for treatment, prevention, and diagnosis of
 XX disorders such as prostate cancer -
 XX Claim 11; Page 2151-2153; 2338bp; English.
 XX AAF1556 to AAF16505 encode the human prostate cancer associated
 XX proteins, called prostate cancer antigens, given in AAB56363 to AAB57302.
 XX The prostate cancer antigens can have neuroprotective, cytoskeletal,
 XX cardioactive, immunomodulatory, muscular, vulnary, gastrointestinal,
 XX nephroprotective, antiinfective, gynaecological and antibacterial activities,
 XX and can be used in gene therapy. The prostate cancer antigen
 XX polynucleotides may be used for detection of prostate cancer, chromosome
 XX identification, as chromosome markers, and for numerous other diagnostic
 XX or research purposes. The prostate cancer antigens may be used to treat
 XX disorders such as neural, immune, muscular, reproductive,
 XX gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
 XX disorders, wounds, and infectious diseases. AAF1556 to AAF16514 to
 XX AAB57303 represent sequences used in the exemplification of the present
 XX invention.
 XX Sequence 519 AA;
 QY 964 MEGEDVEDD 972
 Db 41 MEGEDVEDD 49
 Query Match 0.9%; Score 9; DB 21; Length 519;
 Best Local Similarity 100.0%; Pred. No. 4;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Search completed: April 22, 2003, 15:33:47
Job time : 88 secs

	RESULT 100	
AAM78689	* AAM78689 standard; Protein; 748 AA..	
ID	AAM78689	
XX		
AC	AAM78689;	
XX		
DT	06-NOV-2001 (first entry)	
XX		
XX	Human protein SEQ ID NO 1351.	
KM	Human; cytokine; cell proliferation; cell differentiation; gene therapy; vaccine; peptide therapy; stem cell growth factor; haematopoiesis; tissue growth factor; immunomodulatory; cancer; leukaemia; nervous system disorder; arthritis; inflammation.	
OS	Homo sapiens.	
PX	WO200157190-A2.	
PD		
XX	09-AUG-2001.	
PF		
PR	05-FEB-2001; 2001WO-US04098.	
PR	03-FEB-2000; 2000US-0496914.	
PR	27-APR-2000; 2000US-0560875.	
PR	20-JUN-2000; 2000US-0598075.	
PR	19-JUL-2000; 2000US-0620325.	
PR	01-SEP-2000; 2000US-0654936.	
PR	15-SEP-2000; 2000US-0663561.	
PR	20-OCT-2000; 2000US-0693325.	
PR	30-NOV-2000; 2000US-0728422.	
PA	(HYSE-) HYSEQ INC.	
PI	Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Gao Y, Ma Y, Zhao QA, Wang J, Zhang J, Ren F, Chen R, Wang ZW; Xiue AJ, Yang Y, Wejrhman T, Goodrich R; WPI, 2001-476283/51. N-PSDB; AAK51822.	
PT	Nucleic acids encoding polypeptides with cytokine-like activities, useful in diagnosis and gene therapy -	
PS	Claim 20; Page 3596-3597; 6221pp; English.	
CC	The invention relates to polymaleotides (AAK51456-AAK53435) and the encoded polypeptides (AAM78323-AAK80302) that exhibit activity elating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polymaleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haematopoietic regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation.	
CC	Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the sequence listing were missing at the time of publication.	
SQ	Sequence 748 AA;	
Query Match	0.9%; Score 9; DB 22; Length 748;	
Best Local Similarity	100.0%; Pred. No. 5.6;	
Matches	9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Oy	964 MEGEDVEDD 972	
db	 8 MEGEDVEDD 16	

